Interaction_Description,Simplified_Description
Trioxsalen may increase the photosensitizing activities of Verteporfin.,"When trioxsalen and verteporfin are used together, the skin may become more sensitive to light, potentially leading to increased photosensitivity reactions."
Aminolevulinic acid may increase the photosensitizing activities of Verteporfin.,"Aminolevulinic acid can make your skin more sensitive to light when used with Verteporfin, which could cause skin reactions like burning or redness"
Titanium dioxide may increase the photosensitizing activities of Verteporfin.,Titanium dioxide can make your skin more sensitive to light when used with Verteporfin which might cause skin reactions.
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Verteporfin.,Using Paclitaxel with Verteporfin can increase the chances of side effects or make them worse.
The risk or severity of adverse effects can be increased when Docetaxel is combined with Verteporfin.,Combining Docetaxel with Verteporfin can raise the risk of experiencing more severe side effects.
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Verteporfin.,"When Cabazitaxel is used with Verteporfin, it can make side effects more likely or severe."
Aminolevulinic acid may decrease the cardiotoxic activities of Digoxin.,Aminolevulinic acid may lower the harmful effects of Digoxin on the heart.
Temoporfin may decrease the cardiotoxic activities of Digoxin.,Temoporfin may lower the harmful effects of Digoxin on the heart.
Cyclophosphamide may decrease the cardiotoxic activities of Digoxin.,Cyclophosphamide may lower the harmful effects of Digoxin on the heart.
Paclitaxel may decrease the cardiotoxic activities of Digoxin.,Paclitaxel may decrease the risk of side effects on the heart when used with Digoxin.
Docetaxel may decrease the cardiotoxic activities of Digoxin.,Docetaxel may lower the risk of side effects when used with Digoxin.
Cabazitaxel may decrease the cardiotoxic activities of Digoxin.,Cabazitaxel may lower the risk of side effects when used with Digoxin.
The serum concentration of Digoxin can be decreased when it is combined with Bosentan.,Combining Bosentan with Digoxin can lower the concentration of Digoxin in the blood.
The serum concentration of Digoxin can be decreased when it is combined with Lumacaftor.,"When Digoxin is taken with Lumacaftor, its serum concentration may be reduced."
The serum concentration of Digoxin can be increased when it is combined with Silodosin.,Using Silodosin along with Digoxin may increase the amount of Digoxin in the bloodstream.
The serum concentration of Digoxin can be increased when it is combined with Edoxaban.,Taking Digoxin with Edoxaban can result in higher levels of Digoxin in the blood.
Anagrelide may decrease the cardiotoxic activities of Digoxin.,Anagrelide can reduce the harmful effects of Digoxin on the heart.
Carboplatin may decrease the cardiotoxic activities of Digoxin.,Carboplatin can lower the heart-related risks of Digoxin.
The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digoxin.,Combining Etacrynic acid with Digoxin may increase the chance of harmful side effects.
Procarbazine may decrease the cardiotoxic activities of Digoxin.,Procarbazine can reduce the heart-related risks of Digoxin.
The serum concentration of Digoxin can be decreased when it is combined with Acarbose.,Acarbose can lower the amount of Digoxin in the blood.
Sunitinib may decrease the cardiotoxic activities of Digoxin.,Sunitinib can reduce the harmful effects of Digoxin on the heart.
Lanreotide may decrease the cardiotoxic activities of Digoxin.,Lanreotide can reduce the harmful effects of Digoxin on the heart.
Brimonidine may increase the bradycardic activities of Digoxin.,Brimonidine can make Digoxin slow the heart rate more.
Imatinib may decrease the cardiotoxic activities of Digoxin.,Imatinib can lower the harmful effects of Digoxin on the heart.
Crizotinib may decrease the cardiotoxic activities of Digoxin.,Crizotinib can lower the harmful effects of Digoxin on the heart.
The serum concentration of Digoxin can be decreased when it is combined with Mitotane.,Mitotane can lower the amount of Digoxin in the blood.
Dienogest may decrease the cardiotoxic activities of Digoxin.,Dienogest can reduce the harmful effects of Digoxin on the heart.
Olaparib may decrease the cardiotoxic activities of Digoxin.,Olaparib can reduce the harmful effects of Digoxin on the heart.
Rucaparib may decrease the cardiotoxic activities of Digoxin.,Rucaparib can reduce the harmful effects of Digoxin on the heart.
Prednisolone may decrease the cardiotoxic activities of Digoxin.,Prednisolone can reduce the harmful effects of Digoxin on the heart.
Midostaurin may decrease the cardiotoxic activities of Digoxin.,Midostaurin can lower the harmful effects of Digoxin on the heart.
Medroxyprogesterone acetate may decrease the cardiotoxic activities of Digoxin.,Medroxyprogesterone acetate can reduce the harmful effects of Digoxin on the heart.
Bortezomib may decrease the cardiotoxic activities of Digoxin.,Bortezomib can lower the harmful effects of Digoxin on the heart.
Panobinostat may decrease the cardiotoxic activities of Digoxin.,Panobinostat can reduce the harmful effects of Digoxin on the heart.
Betaxolol may increase the bradycardic activities of Digoxin.,Betaxolol can make Digoxin slow the heart rate more.
The serum concentration of Digoxin can be decreased when it is combined with Enzalutamide.,Enzalutamide can lower the amount of Digoxin in the blood.
Abiraterone may decrease the cardiotoxic activities of Digoxin.,Abiraterone can reduce the harmful effects of Digoxin on the heart.
Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin.,Diethylstilbestrol can reduce the harmful effects of Digoxin on the heart.
Nilotinib may decrease the cardiotoxic activities of Digoxin.,Nilotinib can lower the harmful effects of Digoxin on the heart.
Dexamethasone may decrease the cardiotoxic activities of Digoxin.,Dexamethasone can reduce the harmful effects of Digoxin on the heart.
Letrozole may decrease the cardiotoxic activities of Digoxin.,Letrozole can reduce the harmful effects of Digoxin on the heart.
Norfloxacin may decrease the cardiotoxic activities of Digoxin.,Norfloxacin can reduce the harmful effects of Digoxin on the heart.
Miltefosine may decrease the cardiotoxic activities of Digoxin.,Miltefosine can lower the harmful effects of Digoxin on the heart.
Trimetrexate may decrease the cardiotoxic activities of Digoxin.,Trimetrexate can reduce the harmful effects of Digoxin on the heart.
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digoxin.,Combining Amphotericin B with Digoxin may increase the chance of harmful side effects.
Sirolimus may decrease the cardiotoxic activities of Digoxin.,Sirolimus can reduce the harmful effects of Digoxin on the heart.
Alprenolol may increase the bradycardic activities of Digoxin.,Alprenolol can make Digoxin slow the heart rate more.
Timolol may increase the bradycardic activities of Digoxin.,Timolol can make Digoxin slow the heart rate more.
Atenolol may increase the bradycardic activities of Digoxin.,Atenolol can make Digoxin slow the heart rate more.
Bupranolol may increase the bradycardic activities of Digoxin.,Bupranolol can make Digoxin slow the heart rate more.
Celiprolol may increase the bradycardic activities of Digoxin.,Celiprolol can make Digoxin slow the heart rate more.
Oxprenolol may increase the bradycardic activities of Digoxin.,Oxprenolol can make Digoxin slow the heart rate more.
Metoprolol may increase the bradycardic activities of Digoxin.,Metoprolol can make Digoxin slow the heart rate more.
Bopindolol may increase the bradycardic activities of Digoxin.,Bopindolol can make Digoxin slow the heart rate more.
Megestrol acetate may decrease the cardiotoxic activities of Digitoxin.,Megestrol acetate can reduce the harmful effects of Digitoxin on the heart.
Fleroxacin may decrease the cardiotoxic activities of Digitoxin.,Fleroxacin can reduce the harmful effects of Digitoxin on the heart.
Phenylbutyric acid may decrease the cardiotoxic activities of Digitoxin.,Phenylbutyric acid can reduce the harmful effects of Digitoxin on the heart.
Trifluridine may decrease the cardiotoxic activities of Digitoxin.,Trifluridine can reduce the harmful effects of Digitoxin on the heart.
Medrogestone may decrease the cardiotoxic activities of Digitoxin.,Medrogestone can reduce the harmful effects of Digitoxin on the heart.
Lycopene may decrease the cardiotoxic activities of Digitoxin.,Lycopene can reduce the harmful effects of Digitoxin on the heart.
The serum concentration of Digitoxin can be decreased when it is combined with Deferasirox.,Deferasirox can lower the amount of Digitoxin in the blood.
The serum concentration of Digitoxin can be decreased when it is combined with Kaolin.,Kaolin can lower the amount of Digitoxin in the blood.
The therapeutic efficacy of Digitoxin can be decreased when used in combination with Spironolactone.,Spironolactone can reduce how well Digitoxin works when used together.
Labetalol may increase the bradycardic activities of Digitoxin.,Labetalol can make Digitoxin slow the heart rate more.
Carvedilol may increase the bradycardic activities of Digitoxin.,Carvedilol can make Digitoxin slow the heart rate more.
The serum concentration of Digitoxin can be decreased when it is combined with Mesalazine.,Mesalazine can lower the amount of Digitoxin in the blood.
The serum concentration of Digitoxin can be decreased when it is combined with Balsalazide.,Balsalazide can lower the amount of Digitoxin in the blood.
The serum concentration of Digitoxin can be decreased when it is combined with Olsalazine.,Olsalazine can lower the amount of Digitoxin in the blood.
Resveratrol may decrease the cardiotoxic activities of Digitoxin.,Resveratrol can reduce the harmful effects of Digitoxin on the heart.
The serum concentration of Digitoxin can be increased when it is combined with Conivaptan.,Conivaptan can increase the amount of Digitoxin in the blood.
Bisoprolol may increase the bradycardic activities of Digitoxin.,Bisoprolol can make Digitoxin slow the heart rate more.
Penbutolol may increase the bradycardic activities of Digitoxin.,Penbutolol can make Digitoxin slow the heart rate more.
Nebivolol may increase the bradycardic activities of Digitoxin.,Nebivolol can make Digitoxin slow the heart rate more.
Acebutolol may increase the bradycardic activities of Digitoxin.,Acebutolol can make Digitoxin slow the heart rate more.
Carteolol may increase the bradycardic activities of Digitoxin.,Carteolol can make Digitoxin slow the heart rate more.
Vandetanib may decrease the cardiotoxic activities of Digitoxin.,Vandetanib can reduce the harmful effects of Digitoxin on the heart.
Sotalol may increase the bradycardic activities of Digitoxin.,Sotalol can make Digitoxin slow the heart rate more.
Levobunolol may increase the bradycardic activities of Digitoxin.,Levobunolol can make Digitoxin slow the heart rate more.
Pindolol may increase the bradycardic activities of Digitoxin.,Pindolol can make Digitoxin slow the heart rate more.
Metipranolol may increase the bradycardic activities of Digitoxin.,Metipranolol can make Digitoxin slow the heart rate more.
The serum concentration of Deslanoside can be decreased when it is combined with Netilmicin.,Netilmicin can lower the amount of Deslanoside in the blood.
The serum concentration of Deslanoside can be decreased when it is combined with Amikacin.,Amikacin can lower the amount of Deslanoside in the blood.
Valrubicin may decrease the cardiotoxic activities of Deslanoside.,Valrubicin can reduce the harmful effects of Deslanoside on the heart.
Daunorubicin may decrease the cardiotoxic activities of Deslanoside.,Daunorubicin can reduce the harmful effects of Deslanoside on the heart.
Doxorubicin may decrease the cardiotoxic activities of Deslanoside.,Doxorubicin can reduce the harmful effects of Deslanoside on the heart.
The serum concentration of Deslanoside can be decreased when it is combined with Arbekacin.,Arbekacin can lower the amount of Deslanoside in the blood.
The serum concentration of Deslanoside can be decreased when it is combined with Gentamicin.,Gentamicin can lower the amount of Deslanoside in the blood.
The serum concentration of Deslanoside can be decreased when it is combined with Paromomycin.,Paromomycin can lower the amount of Deslanoside in the blood.
The serum concentration of Deslanoside can be decreased when it is combined with Spectinomycin.,Spectinomycin can lower the amount of Deslanoside in the blood.
Prednisone may decrease the cardiotoxic activities of Deslanoside.,Prednisone can reduce the harmful effects of Deslanoside on the heart.
Diltiazem may increase the atrioventricular blocking (AV block) activities of Ouabain.,"Diltiazem and Ouabain both slow heart conduction; using them together increases the risk of AV block, which can cause slow heart rate or fainting."
Verapamil may increase the atrioventricular blocking (AV block) activities of Ouabain.,"Verapamil enhances the AV-blocking effect of Ouabain, raising the chance of dangerously slow heart rhythms."
Tiaprofenic acid may increase the neuroexcitatory activities of Gatifloxacin.,"Combining Tiaprofenic acid with Gatifloxacin may overstimulate the nervous system, increasing the risk of seizures or agitation."
The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Gatifloxacin.,"This combination can enhance harmful side effects such as tendon damage, blood sugar changes, or immune suppression."
The risk or severity of adverse effects can be increased when Formestane is combined with Gatifloxacin.,"Formestane and Gatifloxacin may have additive toxicities, leading to stronger or more frequent adverse reactions."
The serum concentration of Gatifloxacin can be decreased when it is combined with Sucralfate.,"Sucralfate can bind to Gatifloxacin in the gut, lowering its absorption and effectiveness."
Mesalazine may increase the neuroexcitatory activities of Gatifloxacin.,"This combination may heighten nervous system activity, leading to a higher risk of tremors or seizures."
Balsalazide may increase the neuroexcitatory activities of Gatifloxacin.,"The interaction may intensify nervous system stimulation, possibly resulting in neurotoxic symptoms."
Olsalazine may increase the neuroexcitatory activities of Gatifloxacin.,"These drugs together may increase excitability in the brain and nerves, leading to agitation or seizures."
Resveratrol may increase the neuroexcitatory activities of Gatifloxacin.,"Resveratrol may amplify the nervous side effects of Gatifloxacin, such as restlessness or convulsions."
Masoprocol may increase the neuroexcitatory activities of Gatifloxacin.,"Masoprocol may enhance Gatifloxacin's stimulation of the nervous system, raising seizure risk."
Sulindac may increase the neuroexcitatory activities of Gatifloxacin.,"Sulindac, when combined with Gatifloxacin, may increase brain excitability and seizure potential."
Pirfenidone may increase the neuroexcitatory activities of Gatifloxacin.,This interaction could raise the likelihood of nervous system overstimulation and related symptoms.
Mycophenolate mofetil may increase the neuroexcitatory activities of Gatifloxacin.,Combining these drugs might result in heightened neurological side effects such as confusion or tremors.
Leflunomide may increase the neuroexcitatory activities of Gatifloxacin.,Leflunomide could worsen Gatifloxacin-induced nervous system side effects.
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Gatifloxacin.,"Both drugs can extend the heart's QT interval, potentially leading to life-threatening arrhythmias."
Warfarin may increase the anticoagulant activities of Gatifloxacin.,"Warfarin may intensify the blood-thinning effect of Gatifloxacin, increasing bleeding risk."
Phenprocoumon may increase the anticoagulant activities of Gatifloxacin.,This combination may enhance anticoagulation and elevate the risk of bleeding complications.
Phenindione may increase the anticoagulant activities of Gatifloxacin.,"The interaction may result in excessive blood thinning, increasing susceptibility to bleeding."
Acenocoumarol may increase the anticoagulant activities of Gatifloxacin.,"Combining these may heighten the effect of anticoagulation, raising bleeding risk."
Dicoumarol may increase the anticoagulant activities of Gatifloxacin.,"Dicoumarol may amplify Gatifloxacins anticoagulant action, increasing the danger of hemorrhage."
Rosiglitazone may increase the hypoglycemic activities of Gatifloxacin.,"This combo can overly lower blood sugar, risking hypoglycemia with symptoms like confusion or fainting."
Nimesulide may increase the neuroexcitatory activities of Gatifloxacin.,"Nimesulide might make Gatifloxacin cause more nervous system side effects, like shaking or confusion."
Acetylsalicylic acid may increase the neuroexcitatory activities of Gatifloxacin.,"Taking Acetylsalicylic acid with Gatifloxacin might make the nervous system effects stronger, like agitation or trembling."
Diflunisal may increase the neuroexcitatory activities of Gatifloxacin.,"Diflunisal can increase Glatifloxacin effects on the nervous system, potentially leading to symptoms like seizures or restlessness."
Azelastine may increase the neuroexcitatory activities of Gatifloxacin.,"Azelastine may amplify the nervous system effects of Gatifloxacin, increasing risks of symptoms like tremors."
Tranilast may increase the neuroexcitatory activities of Gatifloxacin.,"Tranilast might make Gatifloxacin overstimulate the nervous system, causing things like confusion or shaking."
Sulfisoxazole may increase the hypoglycemic activities of Gatifloxacin.,"Sulfisoxazole can make Gatifloxacin lower blood sugar too much, causing symptoms like dizziness or fainting."
Chlorpropamide may increase the hypoglycemic activities of Gatifloxacin.,"Chlorpropamide may make Gatifloxacin lower blood sugar too much, increasing the risk of low blood sugar symptoms."
Canagliflozin may increase the hypoglycemic activities of Gatifloxacin.,"Canagliflozin might make Gatifloxacin lower blood sugar too much, leading to symptoms like shakiness."
Pentamidine may increase the hypoglycemic activities of Gatifloxacin.,"Pentamidine can make Gatifloxacin lower blood sugar more than usual, raising the risk of hypoglycemia."
Glipizide may increase the hypoglycemic activities of Gatifloxacin.,"Glipizide may increase the blood sugar-lowering effects of Gatifloxacin, increasing the risk of hypoglycemia."
Glyburide may increase the hypoglycemic activities of Gatifloxacin.,"Glyburide may cause Gatifloxacin to lower blood sugar too much, risking symptoms like dizziness or fainting."
Bromocriptine may increase the hypoglycemic activities of Gatifloxacin.,"Bromocriptine may enhance Glatifloxacin ability to lower blood sugar, possibly leading to hypoglycemia."
Chloroquine may increase the neuroexcitatory activities of Gatifloxacin.,Chloroquine may increase the risk of nervous system side effects when combined with Gatifloxacin.
Celecoxib may increase the neuroexcitatory activities of Gatifloxacin.,"Celecoxib might make Gatifloxacin overstimulate the nervous system, increasing symptoms like confusion."
Salicylic acid may increase the neuroexcitatory activities of Gatifloxacin.,"Salicylic acid could amplify Glatifloxacin effects on the nervous system, potentially causing shaking or seizures."
Naftifine may increase the neuroexcitatory activities of Gatifloxacin.,"Naftifine may increase the likelihood of Gatifloxacin causing nervous system problems, such as tremors."
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Gatifloxacin.,Using Fluticasone propionate with Gatifloxacin can increase the risk of harmful side effects like immune system problems.
The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate.,"Magnesium sulfate may lower the amount of Gatifloxacin in the blood, reducing its effectiveness."
Fenbufen may increase the neuroexcitatory activities of Gatifloxacin.,"Fenbufen might make Gatifloxacin cause more nervous system side effects, like shaking or confusion."
Meclofenamic acid may increase the neuroexcitatory activities of Gatifloxacin.,Meclofenamic acid can increase the likelihood of Gatifloxacin causing nervous system overstimulation.
Tolmetin may increase the neuroexcitatory activities of Gatifloxacin.,Tolmetin may make Gatifloxacin cause more nervous system effects like trembling or seizures.
Tenoxicam may increase the neuroexcitatory activities of Gatifloxacin.,"Tenoxicam can make Gatifloxacin overstimulate the nervous system, causing symptoms like confusion."
Choline magnesium trisalicylate may increase the neuroexcitatory activities of Gatifloxacin.,"Choline magnesium trisalicylate may enhance Glatifloxacin nervous system effects, leading to symptoms like agitation."
Etoricoxib may increase the neuroexcitatory activities of Gatifloxacin.,"Etoricoxib may make Gatifloxacin overstimulate the nervous system, causing restlessness or confusion."
Suprofen may increase the neuroexcitatory activities of Gatifloxacin.,Suprofen can increase the risk of nervous system overstimulation when taken with Gatifloxacin.
Flurbiprofen may increase the neuroexcitatory activities of Gatifloxacin.,"Flurbiprofen may heighten Glatifloxacin nervous system effects, leading to symptoms like shaking or confusion."
Indomethacin may increase the neuroexcitatory activities of Gatifloxacin.,Indomethacin may increase the risk of nervous system side effects when combined with Gatifloxacin.
Oxyphenbutazone may increase the neuroexcitatory activities of Gatifloxacin.,"Oxyphenbutazone can make Gatifloxacin cause stronger nervous system effects, like trembling or seizures."
Icatibant may increase the neuroexcitatory activities of Gatifloxacin.,Icatibant might increase the nervous system overstimulation caused by Gatifloxacin.
Etodolac may increase the neuroexcitatory activities of Gatifloxacin.,"Etodolac can increase Glatifloxacin effects on the nervous system, leading to symptoms like restlessness or shaking."
Adapalene may increase the neuroexcitatory activities of Gatifloxacin.,"Adapalene might make Gatifloxacin overstimulate the nervous system, leading to side effects like confusion."
The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium salicylate.,"Magnesium salicylate can reduce the amount of Gatifloxacin in the bloodstream, lowering its effect."
The serum concentration of Gatifloxacin can be decreased when it is combined with Quinapril.,"Quinapril can lower the amount of Gatifloxacin in the body, reducing how well it works."
The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Gatifloxacin.,Combining Ribociclib with Gatifloxacin can increase the risk of heart problems like abnormal heart rhythms.
The metabolism of Gatifloxacin can be decreased when combined with Theophylline.,"Theophylline can slow down the breakdown of Gatifloxacin in the body, increasing the risk of side effects."
The metabolism of Gatifloxacin can be decreased when combined with Dyphylline.,"Dyphylline can reduce how quickly Gatifloxacin is processed in the body, raising the chances of side effects."
The metabolism of Gatifloxacin can be decreased when combined with Aminophylline.,"Aminophylline can slow the breakdown of Gatifloxacin, increasing the risk of side effects."
The risk or severity of adverse effects can be increased when Prednisolone is combined with Rosoxacin.,"Taking Prednisolone with Rosoxacin can increase the risk of harmful side effects, including immune system issues."
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Rosoxacin.,Combining Dexamethasone with Rosoxacin can increase the chance of harmful side effects like immune issues.
The risk or severity of adverse effects can be increased when Prednisone is combined with Rosoxacin.,"Taking Prednisone with Rosoxacin may increase the risk of negative effects, like immune system problems."
The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rosoxacin.,"Methylprednisolone may make Rosoxacin cause more harmful side effects, such as immune system issues."
The risk or severity of adverse effects can be increased when Formestane is combined with Rosoxacin.,"Formestane can increase the risk of side effects when used with Rosoxacin, including problems with the immune system."
The serum concentration of Rosoxacin can be decreased when it is combined with Sucralfate.,"Sucralfate may lower the amount of Rosoxacin in the bloodstream, reducing its effectiveness."
Mesalazine may increase the neuroexcitatory activities of Rosoxacin.,"Mesalazine may make Rosoxacin overstimulate the nervous system, increasing the risk of side effects like agitation."
Balsalazide may increase the neuroexcitatory activities of Rosoxacin.,"Balsalazide can enhance Rosoxacin effects on the nervous system, leading to symptoms like shaking."
Olsalazine may increase the neuroexcitatory activities of Rosoxacin.,Olsalazine can increase the likelihood of Rosoxacin causing nervous system overstimulation.
Azelastine may increase the neuroexcitatory activities of Rosoxacin.,"Azelastine may enhance Rosoxacin nervous system effects, like confusion or trembling."
Tranilast may increase the neuroexcitatory activities of Rosoxacin.,"Tranilast can make Rosoxacin overstimulate the nervous system, leading to symptoms like restlessness."
Sulfisoxazole may increase the hypoglycemic activities of Rosoxacin.,"Sulfisoxazole can make Rosoxacin lower blood sugar too much, increasing the risk of hypoglycemia."
Chlorpropamide may increase the hypoglycemic activities of Rosoxacin.,"Chlorpropamide may cause Rosoxacin to lower blood sugar more than normal, leading to symptoms like dizziness."
Canagliflozin may increase the hypoglycemic activities of Rosoxacin.,"Canagliflozin may make Rosoxacin lower blood sugar more than usual, increasing the risk of low blood sugar."
Pentamidine may increase the hypoglycemic activities of Rosoxacin.,"Pentamidine may cause Rosoxacin to lower blood sugar too much, leading to symptoms of hypoglycemia."
Glipizide may increase the hypoglycemic activities of Rosoxacin.,"Glipizide can enhance Rosoxacin ability to lower blood sugar, leading to the risk of low blood sugar."
Disopyramide may increase the hypoglycemic activities of Rosoxacin.,"Disopyramide can make Rosoxacin lower blood sugar more than usual, increasing the risk of hypoglycemia."
Tolbutamide may increase the hypoglycemic activities of Rosoxacin.,"Tolbutamide may increase the blood sugar-lowering effects of Rosoxacin, raising the risk of hypoglycemia."
Miglitol may increase the hypoglycemic activities of Rosoxacin.,"Miglitol may increase the ability of Rosoxacin to lower blood sugar, increasing the chances of hypoglycemia."
The risk or severity of adverse effects can be increased when Ciclesonide is combined with Rosoxacin.,"Using Ciclesonide with Rosoxacin can increase the risk of side effects, including immune system issues."
The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Rosoxacin.,"Cortisone acetate may increase the risk of side effects when combined with Rosoxacin, such as problems with the immune system."
The risk or severity of adverse effects can be increased when Alclometasone is combined with Rosoxacin.,"Alclometasone can increase the chance of harmful effects when taken with Rosoxacin, particularly related to the immune system."
The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Rosoxacin.,Fludrocortisone may increase the risk of harmful side effects when combined with Rosoxacin.
The risk or severity of adverse effects can be increased when Flunisolide is combined with Rosoxacin.,"Flunisolide can raise the risk of negative side effects when used with Rosoxacin, like immune system problems."
The risk or severity of adverse effects can be increased when Triamcinolone is combined with Rosoxacin.,"Triamcinolone may make Rosoxacin cause more harmful effects, especially immune system-related side effects."
Fondaparinux may decrease the anticoagulant activities of Estrone.,Fondaparinux may make Estrone less effective at preventing blood clots.
Pentaerythritol tetranitrate may decrease the anticoagulant activities of Estrone.,Pentaerythritol tetranitrate may reduce Estrone’s ability to prevent blood clots.
Citric acid may decrease the anticoagulant activities of Estrone.,Citric acid may make Estrone less effective at preventing blood clots.
Pentosan polysulfate may decrease the anticoagulant activities of Estrone.,Pentosan polysulfate may reduce Estrone’s ability to prevent blood clots.
Protocatechualdehyde may decrease the anticoagulant activities of Estrone.,Protocatechualdehyde may make Estrone less effective in preventing blood clots.
The bioavailability of Estrone can be decreased when combined with Sodium bicarbonate.,Sodium bicarbonate may reduce how much Estrone is absorbed into the bloodstream.
The bioavailability of Estrone can be decreased when combined with Magaldrate.,Magaldrate can reduce how much Estrone gets into the bloodstream.
Tipranavir may increase the dermatologic adverse activities of Estrone.,"Tipranavir may make Estrone cause more skin-related side effects, like irritation or rashes."
The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Teriflunomide.,Tiaprofenic acid may increase the risk of side effects when taken with Teriflunomide.
The risk or severity of adverse effects can be increased when Carprofen is combined with Teriflunomide.,Carprofen may increase the chance of harmful side effects when combined with Teriflunomide.
The metabolism of Teriflunomide can be decreased when combined with Cyclophosphamide.,"Cyclophosphamide can slow down the breakdown of Teriflunomide, increasing its effects."
The serum concentration of Teriflunomide can be increased when it is combined with Paclitaxel.,"Paclitaxel may raise the amount of Teriflunomide in the blood, possibly increasing side effects."
The serum concentration of Teriflunomide can be increased when it is combined with Docetaxel.,"Docetaxel can increase the level of Teriflunomide in the blood, leading to stronger effects."
The metabolism of Teriflunomide can be decreased when combined with Cabazitaxel.,"Cabazitaxel may slow down the breakdown of Teriflunomide, making its effects last longer."
The metabolism of Teriflunomide can be decreased when combined with Phenytoin.,"Phenytoin can slow the breakdown of Teriflunomide, increasing its concentration in the body."
The metabolism of Teriflunomide can be decreased when combined with Rifampicin.,"Rifampicin can reduce the breakdown of Teriflunomide, making its effects stronger."
The metabolism of Teriflunomide can be decreased when combined with Fosphenytoin.,"Fosphenytoin may reduce how quickly Teriflunomide is broken down, leading to higher levels in the blood."
Timolol may decrease the antihypertensive activities of Teriflunomide.,Timolol may make Teriflunomide less effective at lowering blood pressure.
Atenolol may decrease the antihypertensive activities of Teriflunomide.,Atenolol may make Teriflunomide less effective at lowering blood pressure.
Bupranolol may decrease the antihypertensive activities of Teriflunomide.,Bupranolol may make Teriflunomide less effective at lowering blood pressure.
Celiprolol may decrease the antihypertensive activities of Teriflunomide.,Celiprolol may make Teriflunomide less effective at lowering blood pressure.
Oxprenolol may decrease the antihypertensive activities of Teriflunomide.,Oxprenolol may make Teriflunomide less effective at lowering blood pressure.
Metoprolol may decrease the antihypertensive activities of Teriflunomide.,Metoprolol may make Teriflunomide less effective at lowering blood pressure.
Bopindolol may decrease the antihypertensive activities of Teriflunomide.,Bopindolol may make Teriflunomide less effective at lowering blood pressure.
Esmolol may decrease the antihypertensive activities of Teriflunomide.,Esmolol may make Teriflunomide less effective at lowering blood pressure.
The serum concentration of Teriflunomide can be increased when it is combined with Lenvatinib.,The amount of Teriflunomide in the blood can increase when combined with Lenvatinib.
The serum concentration of Teriflunomide can be increased when it is combined with Levofloxacin.,The amount of Teriflunomide in the blood can increase when combined with Levofloxacin.
Epirubicin may decrease the excretion rate of Teriflunomide which could result in a higher serum level.,"Epirubicin can slow down how quickly Teriflunomide is removed from the body, which could lead to higher levels in the blood."
Streptomycin may decrease the excretion rate of Teriflunomide which could result in a higher serum level.,"Streptomycin can slow down how quickly Teriflunomide is removed from the body, which could lead to higher levels in the blood."
Metrizamide may decrease the excretion rate of Teriflunomide which could result in a higher serum level.,"Metrizamide can slow down how quickly Teriflunomide is removed from the body, which could lead to higher levels in the blood."
Kanamycin may decrease the excretion rate of Teriflunomide which could result in a higher serum level.,"Kanamycin can slow down how quickly Teriflunomide is removed from the body, which could lead to higher levels in the blood."
Idarubicin may decrease the excretion rate of Teriflunomide which could result in a higher serum level.,"Idarubicin can slow down how quickly Teriflunomide is removed from the body, which could lead to higher levels in the blood."
Plicamycin may decrease the excretion rate of Teriflunomide which could result in a higher serum level.,"Plicamycin can slow down how quickly Teriflunomide is removed from the body, which could lead to higher levels in the blood."
Streptozocin may decrease the excretion rate of Teriflunomide which could result in a higher serum level.,"Streptozocin can slow down how quickly Teriflunomide is removed from the body, which could lead to higher levels in the blood."
Tobramycin may decrease the excretion rate of Teriflunomide which could result in a higher serum level.,"Tobramycin can slow down how quickly Teriflunomide is removed from the body, which could lead to higher levels in the blood."
Framycetin may decrease the excretion rate of Teriflunomide which could result in a higher serum level.,"Framycetin can slow down how quickly Teriflunomide is removed from the body, which could lead to higher levels in the blood."
Netilmicin may decrease the excretion rate of Teriflunomide which could result in a higher serum level.,"Netilmicin can slow down how quickly Teriflunomide is removed from the body, which could lead to higher levels in the blood."
Streptozocin may decrease the excretion rate of Salicylamide which could result in a higher serum level.,"Streptozocin can slow down how Salicylamide is removed from the body, leading to higher levels of Salicylamide in the bloodstream. This could increase the risk of side effects or toxicity from Salicylamide."
Tobramycin may decrease the excretion rate of Salicylamide which could result in a higher serum level.,"Tobramycin has the same effect as Streptozocin, slowing down the excretion of Salicylamide and raising its levels in the body, potentially causing unwanted effects."
Framycetin may decrease the excretion rate of Salicylamide which could result in a higher serum level.,"Framycetin, like Tobramycin and Streptozocin, can decrease the excretion of Salicylamide, leading to higher blood levels and increasing the likelihood of side effects."
Netilmicin may decrease the excretion rate of Salicylamide which could result in a higher serum level.,"Netilmicin can reduce how quickly Salicylamide is cleared from the body, resulting in elevated levels of the drug in the bloodstream, which might cause adverse reactions."
Amikacin may decrease the excretion rate of Salicylamide which could result in a higher serum level.,"Amikacin can also slow the removal of Salicylamide from the body, leading to a higher serum concentration, which can raise the risk of negative effects."
Valrubicin may decrease the excretion rate of Salicylamide which could result in a higher serum level.,"Valrubicin may affect the excretion of Salicylamide, causing it to build up in the blood and increasing the potential for side effects due to higher serum levels."
Daunorubicin may decrease the excretion rate of Salicylamide which could result in a higher serum level.,"Daunorubicin can slow down the excretion rate of Salicylamide, resulting in higher levels of the drug in the bloodstream, which could lead to toxicity."
Doxorubicin may decrease the excretion rate of Salicylamide which could result in a higher serum level.,"Doxorubicin, like Daunorubicin, may reduce how quickly Salicylamide is eliminated from the body, potentially causing higher concentrations in the blood and increasing the risk of side effects."
Arbekacin may decrease the excretion rate of Salicylamide which could result in a higher serum level.,"Arbekacin may have the same effect, decreasing the excretion rate of Salicylamide and leading to elevated serum levels, which could increase the chances of adverse reactions."
Gentamicin may decrease the excretion rate of Salicylamide which could result in a higher serum level.,"Gentamicin may reduce the excretion of Salicylamide, causing higher levels in the bloodstream and possibly raising the risk of unwanted side effects."
Paromomycin may decrease the excretion rate of Salicylamide which could result in a higher serum level.,"Paromomycin can slow down the excretion of Salicylamide, leading to higher blood levels of the drug, increasing the risk of side effects."
Spectinomycin may decrease the excretion rate of Salicylamide which could result in a higher serum level.,"Spectinomycin may also decrease the rate at which Salicylamide is excreted, raising its levels in the bloodstream and increasing the potential for negative effects."
Practolol may decrease the antihypertensive activities of Salicylamide.,"Practolol may interfere with the blood pressure-lowering effects of Salicylamide, making it less effective in treating high blood pressure."
Amiloride may decrease the antihypertensive activities of Salicylamide.,"Amiloride can also reduce the ability of Salicylamide to lower blood pressure, diminishing its antihypertensive effects."
Triamterene may decrease the antihypertensive activities of Salicylamide.,"Triamterene may have the same effect as Amiloride and Practolol, potentially decreasing the blood pressure-lowering effectiveness of Salicylamide."
Isoetharine may increase the hypokalemic activities of Hydroflumethiazide.,"Isoetharine can increase the tendency of Hydroflumethiazide to lower potassium levels in the body, which may lead to symptoms like muscle weakness, cramps, or irregular heartbeats if potassium drops too low."
Doxazosin may increase the hypotensive activities of Hydroflumethiazide.,"Doxazosin can strengthen the blood pressure-lowering effect of Hydroflumethiazide, possibly causing blood pressure to fall too much, leading to dizziness or fainting."
Prazosin may increase the hypotensive activities of Hydroflumethiazide.,"Prazosin may boost the ability of Hydroflumethiazide to lower blood pressure, which can increase the risk of feeling lightheaded, especially when standing up quickly."
Isradipine may increase the hypotensive activities of Hydroflumethiazide.,"Isradipine can make Hydroflumethiazide lower blood pressure more than usual, which might result in excessive drops in blood pressure and related symptoms like tiredness or fainting."
Nicardipine may increase the hypotensive activities of Hydroflumethiazide.,"Nicardipine may enhance the effect of Hydroflumethiazide in lowering blood pressure, increasing the likelihood of low blood pressure and associated side effects like dizziness or blurred vision."
Amlodipine may increase the hypotensive activities of Hydroflumethiazide.,"Amlodipine can increase the blood pressure-lowering activity of Hydroflumethiazide, which might cause your blood pressure to drop too low and make you feel weak or dizzy."
Moexipril may increase the hypotensive activities of Hydroflumethiazide.,"Moexipril may amplify the effect of Hydroflumethiazide on reducing blood pressure, possibly leading to side effects such as fatigue, dizziness, or even fainting in severe cases."
Olmesartan may increase the hypotensive activities of Hydroflumethiazide.,"Olmesartan can make Hydroflumethiazide lower blood pressure more effectively, which could result in low blood pressure symptoms like lightheadedness or confusion."
Nitroprusside may increase the hypotensive activities of Hydroflumethiazide.,"Nitroprusside may intensify the hypotensive effect of Hydroflumethiazide, raising the risk of your blood pressure falling too much and causing circulatory problems or fainting."
Lisinopril may increase the hypotensive activities of Hydroflumethiazide.,"Lisinopril may also boost the blood pressure-lowering action of Hydroflumethiazide, which can result in unwanted side effects like low energy, dizziness, or feeling unsteady."
Nimodipine may increase the hypotensive activities of Hydroflumethiazide.,"Nimodipine may heighten the ability of Hydroflumethiazide to lower blood pressure, potentially leading to very low blood pressure and symptoms like nausea, blurred vision, or confusion."
Minoxidil may increase the hypotensive activities of Hydroflumethiazide.,"Minoxidil can make Hydroflumethiazide reduce blood pressure more aggressively, possibly causing side effects like rapid heartbeat or feeling faint."
Enalapril may increase the hypotensive activities of Hydroflumethiazide.,"Enalapril may strengthen Hydroflumethiazide's effect on lowering blood pressure, which can result in excessive drops in blood pressure, dizziness, or tiredness."
Nicorandil may increase the hypotensive activities of Methyclothiazide.,"Nicorandil can make Methyclothiazide lower your blood pressure more strongly, which might lead to symptoms like dizziness, fainting, or feeling lightheaded due to blood pressure dropping too low."
Clenbuterol may increase the hypokalemic activities of Methyclothiazide.,"Clenbuterol may cause Methyclothiazide to lower potassium levels in the blood more than usual, which can lead to muscle cramps, weakness, or abnormal heart rhythms if potassium becomes too low."
Formoterol may increase the hypokalemic activities of Methyclothiazide.,"Formoterol can increase the effect of Methyclothiazide in reducing potassium levels, raising the risk of hypokalemia and causing possible symptoms like fatigue, muscle spasms, or irregular heartbeat."
Arformoterol may increase the hypokalemic activities of Methyclothiazide.,"Arformoterol may also boost Methyclothiazide’s tendency to lower potassium in the body, which can result in side effects such as muscle pain, weakness, or heart rhythm issues if not monitored."
Dobutamine may increase the hypokalemic activities of Methyclothiazide.,"Dobutamine can make Methyclothiazide reduce potassium levels even more, increasing the chance of developing low potassium-related problems like shakiness, nausea, or heart palpitations."
Prednisolone may increase the hypokalemic activities of Hydroflumethiazide.,"Prednisolone can make Hydroflumethiazide lower potassium levels even more, which might lead to issues like muscle weakness, cramps, or irregular heartbeats due to low potassium in the blood."
The risk or severity of adverse effects can be increased when Bortezomib is combined with Hydroflumethiazide.,"When Bortezomib is taken with Hydroflumethiazide, there’s a greater chance of experiencing harmful side effects, possibly including worsened blood pressure control or increased strain on organs like the kidneys."
Betaxolol may increase the hypotensive activities of Hydroflumethiazide.,"Betaxolol can enhance Hydroflumethiazide’s ability to lower blood pressure, which could lead to dizziness, fainting, or tiredness from a drop in blood pressure that’s too strong."
Dexamethasone may increase the hypokalemic activities of Hydroflumethiazide.,"Dexamethasone may increase Hydroflumethiazide’s potassium-lowering effect, which raises the risk of symptoms like fatigue, heart rhythm problems, or muscle spasms from low potassium levels."
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Hydroflumethiazide.,"Amphotericin B taken together with Hydroflumethiazide can make side effects worse, especially problems related to kidney function or serious electrolyte imbalances like very low potassium."
Timolol may increase the hypotensive activities of Hydroflumethiazide.,"Timolol can boost Hydroflumethiazide’s blood pressure-lowering effect, which might cause you to feel weak, dizzy, or faint due to a stronger-than-expected drop in blood pressure."
Atenolol may increase the hypotensive activities of Hydroflumethiazide.,"Atenolol may also increase the effect of Hydroflumethiazide in lowering blood pressure, possibly causing low blood pressure symptoms like lightheadedness or tiredness."
Celiprolol may increase the hypokalemic activities of Hydroflumethiazide.,"Celiprolol might make Hydroflumethiazide lower potassium even further than usual, increasing the chance of problems such as muscle cramps, weakness, or heart issues."
Metoprolol may increase the hypotensive activities of Hydroflumethiazide.,"Metoprolol may enhance the ability of Hydroflumethiazide to lower blood pressure, which could cause more noticeable effects like dizziness or fainting due to low pressure."
Reserpine may increase the hypotensive activities of Hydroflumethiazide.,"Reserpine can increase how much Hydroflumethiazide lowers blood pressure, which may cause low blood pressure symptoms such as drowsiness, confusion, or a feeling of unsteadiness."
The metabolism of Cyclosporine can be decreased when combined with Dolasetron.,"When Dolasetron is taken with Cyclosporine, it can slow down how quickly Cyclosporine is broken down in the body, which may lead to a buildup of Cyclosporine and raise the risk of side effects like kidney issues or high blood pressure."
The metabolism of Cyclosporine can be decreased when combined with Caffeine.,"Caffeine can also slow the breakdown of Cyclosporine, potentially increasing its levels in the body and raising the chance of toxic effects."
The metabolism of Cyclosporine can be increased when combined with Thiamylal.,"Thiamylal speeds up the breakdown of Cyclosporine, which could lower its effectiveness by reducing how long it stays active in the body."
The metabolism of Cyclosporine can be increased when combined with Methylphenobarbital.,"Methylphenobarbital increases the breakdown rate of Cyclosporine, possibly making it less effective at preventing organ rejection or controlling immune responses."
The metabolism of Cyclosporine can be increased when combined with Amobarbital.,"Amobarbital also causes Cyclosporine to be metabolized more quickly, which might reduce its ability to work properly in the body."
The metabolism of Cyclosporine can be increased when combined with Secobarbital.,"Secobarbital speeds up Cyclosporine metabolism, potentially lowering its levels and reducing its immune-suppressing effects."
The metabolism of Cyclosporine can be increased when combined with Methohexital.,"Methohexital may also cause Cyclosporine to break down faster, which might mean the drug won’t work as well."
The metabolism of Cyclosporine can be increased when combined with Hexobarbital.,"Hexobarbital increases how quickly Cyclosporine is processed, which can lower its effectiveness and may require dose adjustments."
The metabolism of Cyclosporine can be increased when combined with Thiopental.,"Thiopental can cause Cyclosporine to be eliminated more rapidly from the body, which might lead to reduced protection against organ rejection."
The metabolism of Cyclosporine can be decreased when combined with Tamsulosin.,"Tamsulosin slows the breakdown of Cyclosporine, possibly increasing its concentration in the blood and the chance of harmful effects."
The metabolism of Cyclosporine can be decreased when combined with Alfuzosin.,"Alfuzosin also reduces how fast Cyclosporine is metabolized, which could raise its levels and increase the risk of side effects."
The serum concentration of Cyclosporine can be increased when it is combined with Cilostazol.,"When taken with Cilostazol, the amount of Cyclosporine in the blood may increase, raising the chance of toxicity or organ strain."
The metabolism of Cyclosporine can be decreased when combined with Sevoflurane.,"Sevoflurane slows Cyclosporine metabolism, which might cause it to accumulate and heighten the risk of side effects."
The metabolism of Cyclosporine can be decreased when combined with Selegiline.,"Selegiline can also reduce the rate at which Cyclosporine is broken down, potentially increasing its blood levels and unwanted effects."
The metabolism of Cyclosporine can be decreased when combined with Moclobemide.,"Moclobemide may make Cyclosporine stay in the body longer by slowing its breakdown, which can lead to toxicity."
The metabolism of Cyclosporine can be decreased when combined with Vardenafil.,"Vardenafil slows the metabolism of Cyclosporine, possibly leading to higher levels and more intense side effects."
The metabolism of Cyclosporine can be decreased when combined with Tadalafil.,"Tadalafil can also decrease how quickly Cyclosporine is processed, increasing its concentration and the risk of harmful outcomes."
The serum concentration of Cyclosporine can be increased when it is combined with Avanafil.,"Avanafil raises the amount of Cyclosporine in the blood, which can heighten the chance of side effects like kidney damage."
The metabolism of Cyclosporine can be decreased when combined with Buprenorphine.,"Buprenorphine slows how fast Cyclosporine is broken down, which can lead to a buildup and potential toxicity."
The metabolism of Cyclosporine can be decreased when combined with Imipramine.,"Imipramine may decrease the metabolism of Cyclosporine, increasing its levels and risk of adverse effects."
The metabolism of Cyclosporine can be decreased when combined with Ropinirole.,"Ropinirole can slow down the breakdown of Cyclosporine, possibly leading to higher levels in the body and increased side effects."
The metabolism of Cyclosporine can be decreased when combined with Clomipramine.,"Clomipramine may reduce the rate of Cyclosporine metabolism, allowing the drug to build up in the body and increase the risk of harm."
The serum concentration of Cyclosporine can be increased when it is combined with Hydrocodone.,"Hydrocodone can raise the blood concentration of Cyclosporine, potentially leading to more severe side effects or toxicity."
The metabolism of Cyclosporine can be decreased when combined with Ethylmorphine.,"Ethylmorphine slows how quickly Cyclosporine is broken down, which may result in increased levels and higher risk of complications."
Cholic Acid may decrease the excretion rate of Cyclosporine which could result in a higher serum level.,"When Cholic Acid is taken with Cyclosporine, it may reduce how quickly Cyclosporine is removed from the body. This can cause more of the drug to stay in the bloodstream, increasing the risk of side effects like kidney strain or high blood pressure."
Succinylcholine may increase the neuromuscular blocking activities of Cyclosporine.,"Succinylcholine can strengthen the muscle-relaxing effects of Cyclosporine. This may lead to excessive muscle weakness or breathing problems, especially during surgery or anesthesia."
Minocycline can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.,"Minocycline can interfere with the body’s ability to absorb Magnesium salicylate. This means less of the medication enters the bloodstream, possibly making it less effective at relieving pain or inflammation."
Doxycycline can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.,"Doxycycline can also lower how much Magnesium salicylate the body absorbs, which might reduce the drug's ability to work as expected."
Chlortetracycline can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.,"Chlortetracycline can reduce the absorption of Magnesium salicylate, which could result in lower drug levels in the body and weaker pain-relieving or anti-inflammatory effects."
The serum concentration of Magnesium salicylate can be decreased when it is combined with Triethylenetetramine.,"When Magnesium salicylate is taken with Triethylenetetramine, its levels in the blood may drop. This may cause the drug to not work as well, reducing its overall effectiveness."
Lipoic acid can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.,"Lipoic acid can interfere with the absorption of Magnesium salicylate, meaning less of it gets into the bloodstream. This could reduce the medication’s ability to treat symptoms like pain or inflammation."
Orphenadrine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.,"Orphenadrine may increase how much Clozapine slows down brain activity. This can cause stronger drowsiness, confusion, or difficulty thinking clearly, especially in sensitive individuals."
The therapeutic efficacy of Clozapine can be increased when used in combination with Pregabalin.,"Pregabalin may enhance the effectiveness of Clozapine in treating certain mental health symptoms. However, it can also add to side effects like drowsiness or dizziness."
The metabolism of Clozapine can be decreased when combined with Prochlorperazine.,"Prochlorperazine can slow the breakdown of Clozapine in the body. This may lead to higher levels of Clozapine, raising the risk of side effects such as sedation or blood abnormalities."
Suvorexant may increase the central nervous system depressant (CNS depressant) activities of Clozapine.,"Suvorexant can make Clozapine’s sedative effects stronger. This could cause excessive sleepiness, slowed thinking, or breathing issues when both drugs are taken together."
Ethanol may increase the central nervous system depressant (CNS depressant) activities of Clozapine.,"Ethanol (alcohol) can also enhance the brain-slowing effects of Clozapine, increasing the risk of heavy sedation, poor coordination, or dangerous central nervous system depression."
Zolpidem may increase the central nervous system depressant (CNS depressant) activities of Clozapine.,"Zolpidem, a sleep aid, may increase how much Clozapine slows brain activity. This might result in extreme drowsiness or impaired motor skills when both are used together."
Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.,Methotrimeprazine can make Clozapine's sedative effects stronger. This might lead to deeper sleep or more serious mental slowing than expected.
Mirtazapine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.,"Mirtazapine may also increase Clozapine’s effects on the brain, raising the chance of strong drowsiness or slowed responses."
The risk or severity of adverse effects can be increased when Estazolam is combined with Clozapine.,"Taking Estazolam with Clozapine can increase the likelihood of side effects, such as drowsiness, dizziness, or confusion, especially in older adults."
The risk or severity of adverse effects can be increased when Lormetazepam is combined with Clozapine.,"Lormetazepam combined with Clozapine may raise the risk of negative effects, including slowed breathing or excessive sedation."
Paraldehyde may increase the central nervous system depressant (CNS depressant) activities of Clozapine.,"Paraldehyde can intensify Clozapine’s depressant effects on the brain, possibly leading to significant drowsiness or difficulty staying alert."
Clonidine may increase the atrioventricular blocking (AV block) activities of Nebivolol.,"Clonidine can make Nebivolol slow down the electrical signals that pass through the heart more than usual. This might cause a condition called AV block, where the signals from the upper to lower chambers of the heart are delayed or even blocked, potentially leading to a slow heart rate or fainting."
Cabergoline may increase the vasoconstricting activities of Nebivolol.,"Cabergoline may make Nebivolol cause more narrowing of blood vessels. This narrowing, or vasoconstriction, can increase blood pressure or reduce blood flow to certain parts of the body."
Milnacipran may increase the tachycardic activities of Nebivolol.,"Milnacipran can increase the effect Nebivolol has on speeding up the heart rate, a response called tachycardia. While Nebivolol normally lowers heart rate, this combination could lead to unpredictable or uneven heart rhythms."
Apomorphine may increase the atrioventricular blocking (AV block) activities of Nebivolol.,"Apomorphine can make Nebivolol further delay or block the electrical signals in the heart, increasing the chance of developing an AV block. This may result in dizziness, tiredness, or heart rhythm problems."
Norepinephrine may increase the atrioventricular blocking (AV block) activities of Nebivolol.,"Norepinephrine, when used with Nebivolol, can enhance the blocking of heart signals between chambers, leading to a greater risk of AV block. This may cause issues like chest pain, fainting, or fatigue."
Dipivefrin may increase the atrioventricular blocking (AV block) activities of Nebivolol.,"Dipivefrin may make Nebivolol interfere more with heart signal transmission, raising the risk of AV block. This might lead to a slower heartbeat or reduced circulation."
Bethanidine may increase the atrioventricular blocking (AV block) activities of Nebivolol.,"Bethanidine may boost Nebivolol’s ability to slow down the signals passing through the heart, increasing the chance of AV block. This could result in weakness, low blood pressure, or feeling faint."
Epinephrine may increase the atrioventricular blocking (AV block) activities of Nebivolol.,"Epinephrine can strengthen Nebivolol’s blocking effect on heart signal conduction, which may increase the risk of AV block. Symptoms might include chest discomfort or sudden drops in heart rate."
Droxidopa may increase the atrioventricular blocking (AV block) activities of Nebivolol.,"Droxidopa may enhance Nebivolol’s interference with the heart’s electrical system, raising the chance of AV block. This could lead to symptoms like dizziness, lightheadedness, or slow heartbeat."
Nilotinib may increase the QTc-prolonging activities of Propofol.,"Nilotinib may enhance Propofol's ability to lengthen the QT interval on the heart’s electrical rhythm, a condition known as QTc prolongation. This can increase the risk of serious heart rhythm problems like arrhythmias, which could lead to fainting or even life-threatening situations."
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Propofol.,"The risk of harmful effects can be heightened when Amphotericin B is combined with Propofol, potentially leading to increased side effects like heart issues, breathing difficulties, or kidney problems."
The serum concentration of Propofol can be increased when it is combined with Metoprolol.,"Metoprolol may increase the concentration of Propofol in the body, which could intensify its sedative effects. This may result in deeper sedation, respiratory depression, or even unconsciousness."
The risk or severity of adverse effects can be increased when Reserpine is combined with Propofol.,"The risk of side effects can rise when Reserpine is combined with Propofol, leading to enhanced sedation or a drop in blood pressure, causing dizziness, fatigue, or fainting."
Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Propofol.,"Thalidomide can amplify Propofol's sedative effects, increasing the central nervous system depression. This could lead to severe drowsiness, difficulty breathing, or a loss of consciousness."
The risk or severity of adverse effects can be increased when Cabergoline is combined with Propofol.,"The risk of adverse effects can be increased when Cabergoline is used with Propofol. It may lead to stronger sedation or low blood pressure, increasing the chances of dizziness, fainting, or respiratory issues."
Moxifloxacin may increase the QTc-prolonging activities of Propofol.,"Moxifloxacin may increase the QTc-prolonging effects of Propofol, raising the risk of abnormal heart rhythms, which can be dangerous, leading to symptoms like fainting or even cardiac arrest."
Pazopanib may increase the QTc-prolonging activities of Propofol.,"Pazopanib may also enhance the QTc-prolonging effects of Propofol, resulting in an increased risk of heart rhythm disturbances, which can lead to fainting, dizziness, or more severe complications."
Gemifloxacin may increase the QTc-prolonging activities of Propofol.,"Gemifloxacin has similar effects, as it can increase the QTc-prolonging effects of Propofol. This combination may raise the risk of abnormal heart rhythms and other cardiovascular issues."
Ciprofloxacin may increase the QTc-prolonging activities of Propofol.,"Ciprofloxacin may extend the QT interval in conjunction with Propofol, heightening the risk of life-threatening arrhythmias, leading to dizziness, fainting, or more serious heart conditions."
Lenvatinib may increase the QTc-prolonging activities of Propofol.,"Lenvatinib could increase the QTc-prolonging activities of Propofol, which may lead to a higher risk of abnormal heart rhythms and related complications like fainting or cardiac arrest."
Ofloxacin may increase the QTc-prolonging activities of Propofol.,"Ofloxacin may also increase the QTc-prolonging effects of Propofol, enhancing the risk of abnormal heart rhythms, which could cause symptoms like dizziness or fainting."
Toremifene may increase the QTc-prolonging activities of Propofol.,"Toremifene can raise the QTc-prolonging effects of Propofol, which can lead to serious heart rhythm issues, increasing the chance of fainting or more severe heart-related complications."
Arsenic trioxide may increase the QTc-prolonging activities of Propofol.,"Arsenic trioxide may increase the QTc-prolonging effects of Propofol, leading to a higher risk of abnormal heart rhythms and potential cardiovascular events such as fainting or sudden death."
Levofloxacin may increase the QTc-prolonging activities of Propofol.,"Levofloxacin may enhance the QTc-prolonging activities of Propofol, resulting in a higher likelihood of dangerous heart rhythm disturbances and related symptoms such as dizziness or fainting."
Goserelin may increase the QTc-prolonging activities of Propofol.,"Goserelin may also increase the QTc-prolonging effects of Propofol, raising the risk of abnormal heart rhythms, which could cause serious issues such as fainting or more severe cardiovascular complications."
The risk or severity of adverse effects can be increased when Clofarabine is combined with Propofol.,"The risk of adverse effects can increase when Clofarabine is combined with Propofol, potentially leading to more sedation, low blood pressure, or breathing problems."
The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Propofol.,"The risk of harmful effects can be higher when Hydroflumethiazide is combined with Propofol, potentially causing low blood pressure, dizziness, or increased sedation."
The risk or severity of adverse effects can be increased when Barnidipine is combined with Propofol.,"The risk of adverse effects can also increase when Barnidipine is combined with Propofol, leading to more pronounced sedation, dizziness, or drops in blood pressure."
The serum concentration of Propofol can be increased when it is combined with Ibrutinib.,"Ibrutinib may increase the concentration of Propofol in the body, intensifying its sedative effects and possibly causing excessive drowsiness or respiratory issues."
The serum concentration of Propofol can be decreased when it is combined with Dabrafenib.,"Dabrafenib may decrease the concentration of Propofol in the body, potentially making Propofol less effective in inducing sedation, which might lead to a need for higher doses or reduced therapeutic effect."
Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.,"This means that combining these two medications could lead to enhanced sedative effects, potentially causing excessive drowsiness, difficulty breathing, or loss of consciousness."
Aclidinium may increase the anticholinergic activities of Pirenzepine.,"This could enhance side effects like dry mouth, blurred vision, constipation, or difficulty urinating, as both drugs reduce the activity of acetylcholine, a neurotransmitter that helps regulate various bodily functions."
The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pirenzepine.,"The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pirenzepine. Combining these drugs may lead to stronger anticholinergic effects like dry mouth, blurred vision, dizziness, or confusion, as both medications have similar actions on the nervous system."
The risk or severity of adverse effects can be increased when Trospium is combined with Pirenzepine.,"Similar to the above, both drugs can increase anticholinergic effects, raising the likelihood of side effects like constipation, urinary retention, and blurred vision."
The risk or severity of adverse effects can be increased when Atropine is combined with Pirenzepine.,"Combining these medications can lead to an increase in anticholinergic side effects, including dry mouth, constipation, urinary retention, and confusion."
Sulpiride may increase the anticholinergic activities of Methscopolamine bromide.,"This could enhance side effects such as dry mouth, blurred vision, constipation, or urinary retention, as both drugs reduce the activity of acetylcholine."
The therapeutic efficacy of Methscopolamine bromide can be decreased when used in combination with Edrophonium.,"Edrophonium can reverse the effects of anticholinergic drugs like Methscopolamine bromide, potentially reducing its ability to treat symptoms effectively."
The serum concentration of Methscopolamine bromide can be increased when it is combined with Indapamide.,"This could result in higher levels of Methscopolamine bromide in the blood, which might intensify its effects, potentially leading to side effects such as dry mouth, confusion, or blurred vision."
The serum concentration of Methscopolamine bromide can be increased when it is combined with Bendroflumethiazide.,"This could also result in higher blood levels of Methscopolamine bromide, increasing the likelihood of side effects like dizziness or difficulty urinating."
The serum concentration of Methscopolamine bromide can be increased when it is combined with Chlorthalidone.,"Similar to the above, this combination could lead to an increased concentration of Methscopolamine bromide, raising the risk of side effects such as constipation or blurred vision."
The therapeutic efficacy of Methscopolamine bromide can be decreased when used in combination with Isoflurophate.,"Isoflurophate can interfere with the action of anticholinergic drugs like Methscopolamine bromide, potentially reducing its effectiveness."
The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Methscopolamine bromide.,"This combination could enhance the anticholinergic effects, leading to increased side effects like dry mouth, blurred vision, and urinary retention."
The risk or severity of adverse effects can be increased when Orphenadrine is combined with Methscopolamine bromide.,"This combination could lead to intensified anticholinergic effects, resulting in side effects like confusion, dry mouth, and constipation."
Umeclidinium may increase the anticholinergic activities of Methscopolamine bromide.,"This could amplify side effects such as dry mouth, blurred vision, constipation, or urinary retention, as both drugs have anticholinergic properties."
Tiotropium may increase the anticholinergic activities of Methscopolamine bromide.,"Like the above, this combination could lead to stronger anticholinergic effects, resulting in symptoms such as dry mouth, blurred vision, and difficulty urinating."
Glycopyrronium may increase the anticholinergic activities of Methscopolamine bromide.,"This could intensify anticholinergic side effects such as dry mouth, constipation, or urinary retention, as both drugs reduce the activity of acetylcholine."
Tetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Perampanel.,"Combining these drugs could lead to enhanced sedative effects, such as drowsiness, dizziness, or difficulty concentrating, and may increase the risk of respiratory depression."
Pimozide may increase the central nervous system depressant (CNS depressant) activities of Perampanel.,"This combination may result in stronger sedative effects, potentially leading to extreme drowsiness, impaired coordination, or difficulty breathing."
Asenapine may increase the central nervous system depressant (CNS depressant) activities of Perampanel.,"This could cause excessive sedation, leading to fatigue, confusion, or difficulty concentrating, and increase the risk of respiratory issues."
Quetiapine may increase the central nervous system depressant (CNS depressant) activities of Perampanel.,"The combination of these two medications can intensify sedative effects, leading to increased drowsiness, dizziness, and the potential for respiratory depression."
Iloperidone may increase the central nervous system depressant (CNS depressant) activities of Perampanel.,"This combination may lead to stronger sedative effects, including drowsiness, confusion, or difficulty breathing, as both drugs depress the central nervous system."
Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Perampanel.,"This could lead to enhanced sedation, dizziness, or difficulty staying awake, and may increase the risk of respiratory depression."
Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Perampanel.,"Combining these drugs could intensify their sedative effects, leading to excessive drowsiness, difficulty breathing, or impaired coordination."
Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Perampanel.,"The combination may enhance sedation, leading to feelings of extreme drowsiness, dizziness, and potential difficulty breathing."
Thioridazine may increase the central nervous system depressant (CNS depressant) activities of Perampanel.,"This could lead to enhanced sedative effects, such as increased drowsiness, dizziness, or a potential risk of respiratory depression."
Methadone may increase the central nervous system depressant (CNS depressant) activities of Perampanel.,"Combining these medications can lead to a greater sedative effect, potentially resulting in severe drowsiness, impaired motor skills, and difficulty breathing."
Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Perampanel.,"This combination could result in intensified sedative effects, such as excessive drowsiness, dizziness, or trouble breathing."
Clozapine may increase the central nervous system depressant (CNS depressant) activities of Perampanel.,"This could lead to excessive sedation, confusion, difficulty concentrating, and an increased risk of respiratory issues."
Chlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Perampanel.,"The sedative effects could become more pronounced, resulting in drowsiness, dizziness, and potentially dangerous respiratory depression."
Promazine may increase the central nervous system depressant (CNS depressant) activities of Perampanel.,"Combining these medications may intensify sedation, leading to increased drowsiness, confusion, or difficulty breathing."
Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Perampanel.,"This could enhance sedative effects, such as drowsiness and dizziness, and increase the risk of respiratory depression or other central nervous system issues."
Ondansetron may increase the central nervous system depressant (CNS depressant) activities of Perampanel.,"The combination of these drugs could result in enhanced sedation, dizziness, or respiratory issues due to their central nervous system depressant effects."
Diethylpropion may decrease the stimulatory activities of Pipotiazine.,"This combination may reduce the stimulating effects of Pipotiazine, possibly making it less effective at managing certain conditions like schizophrenia or psychosis."
Phentermine may decrease the stimulatory activities of Pipotiazine.,"When used together, Phentermine may reduce the stimulatory effects of Pipotiazine, potentially affecting its therapeutic effectiveness."
Hydroxyamphetamine may decrease the stimulatory activities of Pipotiazine.,"The use of Hydroxyamphetamine with Pipotiazine might lower the stimulating effects of Pipotiazine, which could reduce its intended therapeutic impact."
Lisdexamfetamine may decrease the stimulatory activities of Pipotiazine.,"This combination may lead to a decrease in the stimulatory effects of Pipotiazine, potentially affecting its efficacy in treating psychotic disorders."
Dextroamphetamine may decrease the stimulatory activities of Pipotiazine.,"The stimulating effects of Pipotiazine may be reduced when combined with Dextroamphetamine, which could affect its ability to manage symptoms of certain psychiatric conditions."
Benzphetamine may decrease the stimulatory activities of Pipotiazine.,"When combined, Benzphetamine may diminish the stimulant effects of Pipotiazine, potentially leading to reduced effectiveness in treating psychosis or related disorders."
Metamfetamine may decrease the stimulatory activities of Pipotiazine.,"Metamfetamine can reduce the stimulating effects of Pipotiazine, which may reduce the therapeutic efficacy of Pipotiazine."
Pseudoephedrine may decrease the stimulatory activities of Pipotiazine.,"The use of Pseudoephedrine alongside Pipotiazine may lower the stimulating effects of Pipotiazine, possibly impacting its effectiveness in managing psychiatric symptoms."
Mephentermine may decrease the stimulatory activities of Pipotiazine.,"Combining Mephentermine with Pipotiazine could reduce the stimulant effects of Pipotiazine, potentially making it less effective in treating conditions like schizophrenia or psychosis."
The risk or severity of adverse effects can be increased when Butenafine is combined with Lercanidipine.,"When used together, the combination may increase the risk or severity of side effects like dizziness, low blood pressure, or heart-related problems, as both drugs can affect cardiovascular function."
The risk or severity of adverse effects can be increased when Econazole is combined with Lercanidipine.,"This combination could raise the chances of experiencing side effects such as low blood pressure or dizziness, as both drugs influence cardiovascular systems."
The risk or severity of adverse effects can be increased when Butoconazole is combined with Lercanidipine.,"The combination might lead to a higher likelihood of side effects, such as a drop in blood pressure or dizziness, due to the interactions between the drugs."
The risk or severity of adverse effects can be increased when Oxiconazole is combined with Lercanidipine.,"This drug interaction may elevate the risks of side effects, such as hypotension (low blood pressure) or dizziness, since both medications affect blood pressure regulation."
Mivacurium may increase the neuromuscular blocking activities of Lercanidipine.,"When used together, Mivacurium can intensify the effects of Lercanidipine on neuromuscular blocking, leading to muscle weakness or difficulty with breathing, especially during anesthesia or surgery."
Guanfacine may increase the hypotensive activities of Lercanidipine.,"The combination of these two drugs can enhance the blood pressure-lowering effect of Lercanidipine, leading to a significant decrease in blood pressure, potentially causing dizziness or fainting."
Guanadrel may increase the hypotensive activities of Lercanidipine.,"When taken together, these medications can strengthen the blood pressure-lowering effects, possibly leading to low blood pressure symptoms such as dizziness or fainting."
Travoprost may increase the hypotensive activities of Lercanidipine.,"Combining these drugs could lead to a more pronounced decrease in blood pressure, potentially resulting in symptoms like dizziness or lightheadedness."
The serum concentration of Bepridil can be decreased when it is combined with Rifabutin.,"Rifabutin may reduce the effectiveness of Bepridil by lowering its concentration in the blood, which might diminish its ability to treat certain heart conditions."
The serum concentration of Bepridil can be increased when it is combined with Phenytoin.,"This combination can increase the blood levels of Bepridil, which might lead to an increased risk of side effects, including heart-related issues."
The serum concentration of Bepridil can be decreased when it is combined with Rifampicin.,"Rifampicin can lower the effectiveness of Bepridil by reducing its concentration in the bloodstream, potentially decreasing its ability to treat heart problems."
The serum concentration of Bepridil can be increased when it is combined with Fosphenytoin.,"This combination can elevate Bepridil's blood levels, which may increase the risk of side effects, including cardiovascular issues."
The metabolism of Bepridil can be increased when combined with Primidone.,"Primidone may speed up the breakdown of Bepridil, which could reduce its effectiveness in treating heart conditions."
Phenobarbital may increase the hypotensive activities of Bepridil.,"This combination may enhance Bepridil's ability to lower blood pressure, leading to potential risks such as dizziness or fainting due to low blood pressure."
The metabolism of Bepridil can be increased when combined with Pentobarbital.,"Pentobarbital may accelerate the metabolism of Bepridil, leading to lower blood levels of Bepridil and potentially reducing its therapeutic effects."
The serum concentration of Bepridil can be decreased when it is combined with Rifapentine.,"Rifapentine may lower the concentration of Bepridil in the bloodstream, potentially reducing its effectiveness in treating heart conditions."
The serum concentration of Bepridil can be increased when it is combined with Rifaximin.,"This combination can lead to higher blood levels of Bepridil, which may increase the risk of side effects, particularly those affecting the heart."
Bosentan may increase the hypotensive activities of Bepridil.,"The combination of these drugs may enhance Bepridil's blood pressure-lowering effect, possibly leading to symptoms of low blood pressure, such as dizziness or fainting."
Argatroban may increase the anticoagulant activities of Prasugrel.,"When combined, the anticoagulant effects of both drugs may be enhanced, increasing the risk of bleeding or other complications related to blood clotting."
Bivalirudin may increase the anticoagulant activities of Prasugrel.,"This combination could intensify the blood-thinning effects, which may increase the risk of bleeding."
Dabigatran etexilate may increase the anticoagulant activities of Prasugrel.,"Combining these drugs could lead to an enhanced anticoagulant effect, raising the risk of bleeding."
Edetic acid may increase the anticoagulant activities of Prasugrel.,"This combination might intensify the anticoagulant effects of Prasugrel, potentially increasing bleeding risk."
Fondaparinux may increase the anticoagulant activities of Prasugrel.,The combination of these drugs may elevate the risk of bleeding due to enhanced blood-thinning effects.
Pentaerythritol tetranitrate may increase the anticoagulant activities of Prasugrel.,This combination could enhance the anticoagulant effect and increase the risk of bleeding.
Citric acid may increase the anticoagulant activities of Prasugrel.,"When used together, the blood-thinning effects may be heightened, increasing the risk of bleeding complications."
The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Prasugrel.,Combining these drugs may raise the risk of bleeding or other adverse effects related to their anticoagulant actions.
Protocatechualdehyde may increase the anticoagulant activities of Prasugrel.,"This combination could enhance the anticoagulant effects, increasing the risk of bleeding or bruising."
The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Ranitidine resulting in a loss in efficacy.,This interaction may lower the effectiveness of Prasugrel in preventing blood clots.
The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Cobicistat resulting in a loss in efficacy.,This interaction can reduce the effectiveness of Prasugrel in preventing blood clots.
The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Boceprevir resulting in a loss in efficacy.,"This drug interaction can reduce the effectiveness of Prasugrel, compromising its ability to prevent blood clots."
Cangrelor may decrease the antiplatelet activities of Prasugrel.,"When used together, this combination could reduce the platelet-inhibiting effects of Prasugrel, diminishing its ability to prevent blood clots."
Triflusal may increase the anticoagulant activities of Prasugrel.,"The combination of these two drugs may enhance the blood-thinning effects, raising the risk of bleeding."
Selexipag may increase the anticoagulant activities of Prasugrel.,"This combination could intensify the anticoagulant effects, increasing the risk of bleeding."
Vorapaxar may increase the anticoagulant activities of Prasugrel.,"This combination may result in an increased anticoagulant effect, heightening the risk of bleeding complications."
Betaxolol may decrease the bronchodilatory activities of Clenbuterol.,"When combined, the bronchodilatory effects of Clenbuterol may be reduced, limiting its effectiveness in opening airways."
Alprenolol may decrease the bronchodilatory activities of Clenbuterol.,"The combination could reduce Clenbuterol's ability to dilate the airways, making it less effective for respiratory conditions."
Timolol may decrease the bronchodilatory activities of Clenbuterol.,"This interaction can diminish Clenbuterol's ability to open the airways, reducing its effectiveness in treating conditions like asthma."
Atenolol may decrease the bronchodilatory activities of Clenbuterol.,"When used together, this combination may impair Clenbuterol's ability to promote bronchodilation, reducing its therapeutic effect."
Bupranolol may decrease the bronchodilatory activities of Clenbuterol.,"The combination can limit the effectiveness of Clenbuterol in dilating the airways, potentially worsening respiratory symptoms."
Celiprolol may decrease the bronchodilatory activities of Clenbuterol.,"This interaction can reduce Clenbuterol's ability to act as a bronchodilator, leading to less effective treatment of respiratory issues."
Oxprenolol may decrease the bronchodilatory activities of Clenbuterol.,"This drug interaction may reduce the bronchodilatory effects of Clenbuterol, affecting its ability to open the airways."
Metoprolol may decrease the bronchodilatory activities of Clenbuterol.,"The combination could reduce Clenbuterol's effectiveness in dilating the airways, leading to reduced therapeutic outcomes for respiratory conditions."
Bopindolol may decrease the bronchodilatory activities of Clenbuterol.,"When combined, this may reduce Clenbuterol's bronchodilatory effect, making it less effective in treating respiratory issues."
Esmolol may decrease the bronchodilatory activities of Clenbuterol.,"The bronchodilatory effects of Clenbuterol may be diminished, potentially reducing its therapeutic effectiveness for asthma or other lung conditions."
Milnacipran may increase the tachycardic activities of Clenbuterol.,"When combined, this could lead to an increase in heart rate, which may cause side effects related to excessive stimulation of the heart."
The serum concentration of Clenbuterol can be decreased when it is combined with Cyproterone acetate.,This interaction may lower the effectiveness of Clenbuterol by reducing its concentration in the body.
Spironolactone may decrease the vasoconstricting activities of Clenbuterol.,"When used together, this may reduce Clenbuterol's ability to constrict blood vessels, impacting its intended effects."
The risk or severity of adverse effects can be increased when Labetalol is combined with Clenbuterol.,"This combination could increase the risk of side effects, such as heart rate changes or blood pressure fluctuations."
Carvedilol may decrease the vasoconstricting activities of Clenbuterol.,"This drug interaction may reduce Clenbuterol's ability to induce vasoconstriction, potentially affecting its efficacy."
Bisoprolol may decrease the bronchodilatory activities of Clenbuterol.,"This interaction can impair Clenbuterol's ability to dilate the airways, potentially making it less effective in treating respiratory conditions."
Penbutolol may decrease the bronchodilatory activities of Clenbuterol.,"When combined, this combination may reduce Clenbuterol's effectiveness in promoting bronchodilation, leading to worsened respiratory symptoms."
The serum concentration of Metoclopramide can be increased when it is combined with Succinylcholine.,"This interaction may raise the concentration of Metoclopramide, potentially enhancing its effects and increasing the risk of side effects."
The risk or severity of adverse effects can be increased when Metyrosine is combined with Metoclopramide.,"This combination may increase the likelihood of adverse effects, requiring careful monitoring."
The risk or severity of adverse effects can be increased when Rivastigmine is combined with Metoclopramide.,"The interaction could heighten the risk of side effects, particularly those related to the central nervous system."
Anagrelide may increase the QTc-prolonging activities of Histrelin.,"This combination could lead to a greater risk of QTc interval prolongation, which may cause serious heart rhythm disturbances."
Crizotinib may increase the QTc-prolonging activities of Histrelin.,"The interaction between these two drugs may elevate the risk of QTc prolongation, which is a potential concern for heart arrhythmias."
Panobinostat may increase the QTc-prolonging activities of Histrelin.,"This drug combination could prolong the QTc interval, increasing the risk of serious heart arrhythmias."
Nilotinib may increase the QTc-prolonging activities of Histrelin.,"When used together, these medications can increase the risk of QTc interval prolongation, which may lead to dangerous heart rhythm disturbances."
Moxifloxacin may increase the QTc-prolonging activities of Histrelin.,The combination of these two drugs may significantly increase the risk of QTc prolongation and related heart issues.
Pazopanib may increase the QTc-prolonging activities of Histrelin.,"The risk of QTc prolongation could be heightened when these drugs are used together, which may pose a risk to heart health."
Gemifloxacin may increase the QTc-prolonging activities of Histrelin.,"This drug interaction may lead to prolonged QTc intervals, increasing the risk of heart arrhythmias."
Ciprofloxacin may increase the QTc-prolonging activities of Histrelin.,"The combination could raise the risk of QTc interval prolongation, which may lead to serious heart rhythm disturbances."
Lenvatinib may increase the QTc-prolonging activities of Histrelin.,"The risk of QTc prolongation may be increased when these drugs are used together, potentially leading to arrhythmias."
Ofloxacin may increase the QTc-prolonging activities of Histrelin.,"This interaction could cause a prolonged QTc interval, increasing the risk of arrhythmias and other cardiac issues."
Toremifene may increase the QTc-prolonging activities of Histrelin.,"The combination of these drugs could prolong the QTc interval, raising the risk of dangerous heart arrhythmias."
Arsenic trioxide may increase the QTc-prolonging activities of Histrelin.,This drug interaction could increase the risk of QTc prolongation and associated cardiac risks.
Levofloxacin may increase the QTc-prolonging activities of Histrelin.,"The combination could result in prolonged QTc intervals, increasing the risk of heart arrhythmias."
Goserelin may increase the QTc-prolonging activities of Histrelin.,"The interaction between these drugs may heighten the risk of QTc prolongation, leading to potential heart rhythm disturbances."
Vandetanib may increase the QTc-prolonging activities of Histrelin.,"This drug combination may elevate the risk of QTc prolongation, posing a potential danger to heart health."
Sotalol may increase the QTc-prolonging activities of Histrelin.,This combination may significantly increase the risk of QTc prolongation and related heart issues.
Vemurafenib may increase the QTc-prolonging activities of Histrelin.,"The risk of QTc interval prolongation may be heightened, potentially causing serious heart rhythm disturbances."
Ceritinib may increase the QTc-prolonging activities of Histrelin.,"This interaction can prolong the QTc interval, which may lead to dangerous arrhythmias."
Sulfisoxazole may increase the QTc-prolonging activities of Histrelin.,"The combination of these drugs could increase the risk of QTc prolongation, which could result in harmful cardiac effects."
Pentamidine may increase the QTc-prolonging activities of Histrelin.,The use of these drugs together may increase the likelihood of QTc interval prolongation and associated heart risks.
Disopyramide may increase the QTc-prolonging activities of Histrelin.,"The combination may raise the risk of prolonged QTc intervals, which can lead to arrhythmias."
Quinine may increase the QTc-prolonging activities of Histrelin.,This interaction could lead to an increased risk of QTc prolongation and heart rhythm disturbances.
Chloroquine may increase the QTc-prolonging activities of Histrelin.,"The risk of QTc prolongation may be raised when these two drugs are used together, increasing the potential for arrhythmias."
Quinidine may increase the QTc-prolonging activities of Histrelin.,"The combination could significantly increase the risk of QTc prolongation, leading to potential heart rhythm disturbances."
Lopinavir may increase the QTc-prolonging activities of Histrelin.,"This drug interaction may increase the risk of QTc prolongation, which can lead to dangerous cardiac arrhythmias."
The therapeutic efficacy of Fondaparinux can be decreased when used in combination with Hydroxyprogesterone caproate.,This interaction may reduce the effectiveness of Fondaparinux in preventing blood clot formation.
The therapeutic efficacy of Fondaparinux can be decreased when used in combination with Megestrol acetate.,"When combined with Megestrol acetate, the effect of Fondaparinux may be diminished, possibly affecting its anticoagulant action."
The therapeutic efficacy of Fondaparinux can be decreased when used in combination with Medrogestone.,"This combination may reduce the effectiveness of Fondaparinux, which could impact its ability to prevent blood clots."
Warfarin may increase the anticoagulant activities of Fondaparinux.,"The combination of these two medications may enhance the blood-thinning effect, increasing the risk of bleeding."
Phenprocoumon may increase the anticoagulant activities of Fondaparinux.,"The interaction could potentiate the anticoagulant effect, increasing the risk of bleeding."
Acenocoumarol may increase the anticoagulant activities of Fondaparinux.,"This combination may lead to a stronger anticoagulant effect, raising the risk of bleeding."
Rivaroxaban may increase the anticoagulant activities of Fondaparinux.,"The concurrent use of these medications may heighten the anticoagulant effects, increasing the potential for bleeding complications."
Edetic acid may increase the anticoagulant activities of Fondaparinux.,"This interaction could enhance the anticoagulant effect of Fondaparinux, leading to an increased bleeding risk."
Pentaerythritol tetranitrate may increase the anticoagulant activities of Fondaparinux.,"This combination may further increase the anticoagulant effects, raising the risk of bleeding."
Citric acid may increase the anticoagulant activities of Fondaparinux.,"The use of citric acid with Fondaparinux may potentiate its anticoagulant effects, increasing the bleeding risk."
Protocatechualdehyde may increase the anticoagulant activities of Fondaparinux.,"This combination may enhance the anticoagulant effect of Fondaparinux, increasing the risk of bleeding."
The risk or severity of adverse effects can be increased when Vorapaxar is combined with Fondaparinux.,This combination may increase the likelihood of bleeding due to the enhanced anticoagulant effects.
The therapeutic efficacy of Fondaparinux can be decreased when used in combination with Progesterone.,This combination may reduce the effectiveness of Fondaparinux in preventing blood clots.
The therapeutic efficacy of Fondaparinux can be decreased when used in combination with Levonorgestrel.,"The interaction may decrease the anticoagulant effect of Fondaparinux, potentially impacting its efficacy."
The therapeutic efficacy of Fondaparinux can be decreased when used in combination with Etonogestrel.,This combination may diminish the effectiveness of Fondaparinux in preventing blood clot formation.
The therapeutic efficacy of Fondaparinux can be decreased when used in combination with Allylestrenol.,"When used together, these drugs may reduce the effectiveness of Fondaparinux in preventing blood clots."
Acenocoumarol may increase the anticoagulant activities of Edetic acid.,"This combination could potentiate the blood-thinning effect, increasing the risk of bleeding."
Rivaroxaban may increase the anticoagulant activities of Edetic acid.,"The concurrent use of these medications may enhance the anticoagulant effect, raising the bleeding risk."
Pentaerythritol tetranitrate may increase the anticoagulant activities of Edetic acid.,"This combination may heighten the anticoagulant effect, increasing the potential for bleeding complications."
Citric acid may increase the anticoagulant activities of Edetic acid.,"The combination of citric acid with Edetic acid could increase the anticoagulant effects, leading to a higher risk of bleeding."
Protocatechualdehyde may increase the anticoagulant activities of Edetic acid.,"This interaction may further enhance the anticoagulant effect, increasing the likelihood of bleeding."
Rivaroxaban may increase the anticoagulant activities of Protocatechualdehyde.,"The combination of these two medications may potentiate the anticoagulant effect, raising the risk of bleeding."
Rivaroxaban may increase the anticoagulant activities of Citric acid.,"The use of Rivaroxaban with Citric acid could increase the anticoagulant effect, leading to an increased bleeding risk."
Pentaerythritol tetranitrate may increase the anticoagulant activities of Citric acid.,"This combination may enhance the anticoagulant effects, increasing the risk of bleeding."
Protocatechualdehyde may increase the anticoagulant activities of Citric acid.,"The concurrent use of these two substances may increase the anticoagulant effect, raising the bleeding risk."
Dienogest may increase the thrombogenic activities of Tranexamic acid.,"This interaction may increase the risk of clot formation, potentially leading to thrombosis."
Medroxyprogesterone acetate may increase the thrombogenic activities of Tranexamic acid.,"When used together, these drugs may heighten the risk of thrombosis."
Drospirenone may increase the thrombogenic activities of Tranexamic acid.,"This combination may enhance the risk of clot formation, increasing the potential for thrombosis."
Levonorgestrel may increase the thrombogenic activities of Tranexamic acid.,The combination of these medications may increase the risk of thrombosis.
Etonogestrel may increase the thrombogenic activities of Tranexamic acid.,This combination may elevate the risk of clot formation and thrombosis.
Norgestrel may increase the thrombogenic activities of Tranexamic acid.,The interaction could lead to an increased risk of thrombosis due to heightened clotting potential.
Ethynodiol diacetate may increase the thrombogenic activities of Tranexamic acid.,"This combination may enhance the risk of clot formation, leading to potential thrombosis."
Desogestrel may increase the thrombogenic activities of Tranexamic acid.,The use of these two medications together may increase the risk of clotting and thrombosis.
Gestodene may increase the thrombogenic activities of Tranexamic acid.,This interaction may raise the risk of thrombosis by promoting clot formation.
Norelgestromin may increase the thrombogenic activities of Tranexamic acid.,This combination could lead to an increased risk of clot formation and thrombosis.
Norgestimate may increase the thrombogenic activities of Tranexamic acid.,The use of these drugs together may heighten the risk of thrombosis.
Betaxolol may increase the bradycardic activities of Rivastigmine.,"The combination of these two medications may result in an increased heart rate-lowering effect, potentially causing bradycardia."
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Rivastigmine.,"This combination could increase the likelihood of side effects, possibly affecting heart rate or cognitive function."
Alprenolol may increase the bradycardic activities of Rivastigmine.,"The concurrent use of these two drugs may lead to an enhanced heart rate-lowering effect, resulting in bradycardia."
Timolol may increase the bradycardic activities of Rivastigmine.,"This combination may intensify the heart rate-lowering effect, increasing the risk of bradycardia."
Atenolol may increase the bradycardic activities of Rivastigmine.,"The use of these medications together may enhance the bradycardic effects, raising the risk of slow heart rate."
Bupranolol may increase the bradycardic activities of Rivastigmine.,"This interaction may lead to an increased heart rate-lowering effect, increasing the potential for bradycardia."
Lamivudine may increase the hepatotoxic activities of Ribavirin.,"This combination may increase the risk of liver toxicity, requiring careful monitoring."
Abacavir may increase the hepatotoxic activities of Ribavirin.,The combination could heighten the risk of liver damage or dysfunction.
Emtricitabine may increase the hepatotoxic activities of Ribavirin.,"Concurrent use may increase the risk of liver toxicity, requiring monitoring of liver function."
Entecavir may increase the hepatotoxic activities of Ribavirin.,"This combination could elevate the risk of liver toxicity, necessitating regular liver function tests."
The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine.,"This combination may increase the potential for side effects, including but not limited to gastrointestinal issues or hematological effects."
The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine.,"Combining these drugs could increase the likelihood of adverse reactions, including hematologic and gastrointestinal effects."
The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine.,"This combination may raise the likelihood of side effects, including potential renal and hematologic issues."
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Trimetazidine.,"This combination may lead to an increased risk of central nervous system-related side effects, including dizziness or extrapyramidal symptoms."
The therapeutic efficacy of Levonordefrin can be decreased when used in combination with Mianserin.,"This interaction may reduce the effectiveness of Levonordefrin, potentially impairing its desired effects."
The therapeutic efficacy of Captodiame can be decreased when used in combination with Yohimbine.,"The combination may reduce the effectiveness of Captodiame, potentially leading to suboptimal therapeutic outcomes."
The therapeutic efficacy of Cloxazolam can be decreased when used in combination with Yohimbine.,"The interaction may diminish the efficacy of Cloxazolam, potentially reducing its therapeutic benefits."
The therapeutic efficacy of Nomegestrol can be decreased when used in combination with Ulipristal.,"This combination may lower the effectiveness of Nomegestrol, potentially affecting contraceptive efficacy."
The therapeutic efficacy of Dydrogesterone can be decreased when used in combination with Ulipristal.,"This interaction could reduce the effectiveness of Dydrogesterone, potentially leading to reduced contraceptive or therapeutic effects."
The risk or severity of adverse effects can be increased when Ganciclovir is combined with Entecavir.,"The combination may increase the likelihood of adverse effects, including hematologic or renal issues."
The risk or severity of adverse effects can be increased when Valganciclovir is combined with Entecavir.,"This combination could elevate the risk of side effects, including kidney or blood-related complications."
Clindamycin can cause a decrease in the absorption of Kaolin resulting in a reduced serum concentration and potentially a decrease in efficacy.,This interaction may require alternative treatment approaches to maintain therapeutic effects.
Lincomycin can cause a decrease in the absorption of Kaolin resulting in a reduced serum concentration and potentially a decrease in efficacy.,"The combination should be used with caution, and alternative therapies may need to be considered."
The risk or severity of adverse effects can be increased when Ascorbic acid is combined with Deferoxamine.,"This combination may enhance the toxicity of Deferoxamine, potentially leading to adverse effects like iron overload or kidney problems."
Tenofovir disoproxil may decrease the excretion rate of Cidofovir which could result in a higher serum level.,This interaction could increase the risk of nephrotoxicity and should be monitored closely.
The serum concentration of Ganciclovir can be increased when it is combined with Tenofovir disoproxil.,"This combination could lead to higher Ganciclovir levels, raising the risk of its side effects, particularly in renal function."
The serum concentration of Valganciclovir can be increased when it is combined with Tenofovir disoproxil.,"This interaction may lead to higher Valganciclovir levels, which could increase the risk of side effects, especially renal toxicity."
The therapeutic efficacy of Lactulose can be decreased when used in combination with L-Glutamine.,"This combination may reduce the effectiveness of Lactulose, potentially decreasing its efficacy in treating constipation."
The serum concentration of Triethylenetetramine can be decreased when it is combined with Calcium glucoheptonate.,"This interaction could reduce the effectiveness of Triethylenetetramine, potentially requiring alternative treatment strategies."
The serum concentration of Triethylenetetramine can be decreased when it is combined with Calcium gluconate.,"The combination may result in reduced Triethylenetetramine levels, decreasing its therapeutic efficacy."
The serum concentration of Triethylenetetramine can be decreased when it is combined with Calcium Phosphate.,"This interaction may lead to a decrease in the serum concentration of Triethylenetetramine, potentially reducing its effectiveness."
Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy.,This could impair the intended therapeutic outcomes of Sodium chloride.
The risk or severity of bleeding can be increased when Betrixaban is combined with Sodium citrate.,"This combination may elevate the risk of bleeding complications, necessitating close monitoring."
The therapeutic efficacy of Gestrinone can be decreased when used in combination with Tipiracil.,"The combination may reduce the effectiveness of Gestrinone, possibly diminishing its intended therapeutic effects."
The therapeutic efficacy of Gestrinone can be decreased when used in combination with Ulipristal.,"This interaction may reduce the therapeutic benefits of Gestrinone, potentially affecting its clinical outcomes."
The therapeutic efficacy of Nonoxynol-9 can be decreased when used in combination with Tipiracil.,"This combination may reduce the effectiveness of Nonoxynol-9, potentially compromising its intended use."
The serum concentration of Choline can be increased when it is combined with Tipiracil.,"This interaction may lead to higher Choline levels, which could require dose adjustments or closer monitoring."
The risk or severity of adverse effects can be increased when Dipyridamole is combined with Regadenoson.,"This combination may elevate the risk of side effects, particularly related to cardiovascular function, requiring careful observation."
The therapeutic efficacy of Phenacemide can be decreased when used in combination with Pregabalin.,"The combination may reduce the therapeutic effects of Phenacemide, possibly affecting its clinical efficacy."
The therapeutic efficacy of Phenacemide can be decreased when used in combination with Mianserin.,"This interaction could decrease the effectiveness of Phenacemide, potentially compromising its intended effects."
The therapeutic efficacy of Phenacemide can be decreased when used in combination with Mefloquine.,"This combination may reduce the effectiveness of Phenacemide, leading to suboptimal treatment outcomes."
The serum concentration of Phenacemide can be decreased when it is combined with Orlistat.,"This interaction may lead to a reduction in Phenacemide levels, potentially affecting its therapeutic efficacy."
Ethanol may increase the neurotoxic activities of Cycloserine.,"This combination could increase the risk of neurological side effects, requiring careful monitoring of patients for toxicity."
The risk or severity of adverse effects can be increased when Isoniazid is combined with Cycloserine.,"This combination may elevate the risk of side effects, particularly related to the nervous system."
The risk or severity of adverse effects can be increased when Ethionamide is combined with Cycloserine.,"This interaction could increase the likelihood of adverse effects, particularly in the nervous system."
The risk or severity of adverse effects can be increased when Ethanol is combined with Ethionamide.,"This combination may heighten the risk of adverse reactions, including liver toxicity and central nervous system effects."
The serum concentration of Ethionamide can be increased when it is combined with Isoniazid.,"This combination may increase the levels of Ethionamide in the blood, potentially enhancing its toxic effects."
The risk or severity of adverse effects can be increased when Ethanol is combined with Phendimetrazine.,"The combination could heighten the risk of adverse effects, particularly on the central nervous system."
The risk or severity of adverse effects can be increased when Ethanol is combined with Acetohydroxamic acid.,"This interaction may increase the potential for side effects, especially related to the liver."
The risk or severity of adverse effects can be increased when Zidovudine is combined with Ribavirin.,"This combination may increase the risk of hematologic toxicities, including anemia and neutropenia."
Zalcitabine may increase the hepatotoxic activities of Ribavirin.,"This interaction could elevate the risk of liver toxicity, requiring close monitoring of liver function."
Stavudine may increase the hepatotoxic activities of Ribavirin.,"The combination may increase the risk of liver damage, requiring liver function monitoring."
Lamivudine may increase the hepatotoxic activities of Ribavirin.,"This interaction could increase the risk of liver toxicity, necessitating close monitoring."
Abacavir may increase the hepatotoxic activities of Ribavirin.,"The combination may increase the risk of liver damage, requiring regular liver function tests."
Emtricitabine may increase the hepatotoxic activities of Ribavirin.,"This combination may raise the risk of liver toxicity, and liver function should be closely monitored."
Entecavir may increase the hepatotoxic activities of Ribavirin.,"The combination may elevate the risk of liver damage, necessitating regular monitoring of liver function."
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfadimethoxine.,"This combination may elevate the risk of side effects, particularly in relation to the gastrointestinal or renal system, requiring close monitoring."
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfamethazine.,"This interaction may increase the likelihood of adverse effects, especially related to the gastrointestinal or renal functions."
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfamerazine.,"The combination may elevate the risk of side effects, particularly affecting the gastrointestinal tract or kidneys."
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfacetamide.,"This interaction may raise the potential for side effects, particularly related to the skin or gastrointestinal system."
The risk or severity of adverse effects can be increased when Methenamine is combined with Sulfacetamide.,"The combination may increase the risk of adverse effects, particularly related to the renal system."
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfamethizole.,"This interaction could enhance the risk of side effects, particularly affecting the gastrointestinal or renal systems."
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Pipazethate.,"This combination may elevate the risk of side effects, requiring monitoring for any adverse reactions."
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfacytine.,"This interaction may raise the potential for side effects, particularly related to the gastrointestinal system or renal function."
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfathiazole.,"This combination may increase the risk of adverse effects, requiring careful monitoring."
The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Bismuth subcitrate potassium.,"This combination may reduce the effectiveness of Bisacodyl, potentially requiring dose adjustments."
The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Tromethamine.,"The interaction may lower the effectiveness of Bisacodyl, potentially reducing its therapeutic outcomes."
The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aluminium.,"This combination may reduce Bisacodyl's effectiveness, possibly requiring alternative treatment options."
The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium hydroxide.,"The combination may lower the effectiveness of Bisacodyl, potentially affecting its intended clinical outcomes."
The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Calcium carbonate.,"This interaction may reduce Bisacodyl's effectiveness, requiring monitoring for alternative treatment strategies."
The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aluminum hydroxide.,"The combination may reduce Bisacodyl's therapeutic effects, potentially affecting the desired outcomes."
The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Almasilate.,"This combination may reduce the effectiveness of Bisacodyl, requiring adjustments or alternative treatments."
The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium trisilicate.,"This interaction may reduce the effectiveness of Bisacodyl, potentially necessitating dose modifications or alternative therapies."
Mecamylamine may increase the neuromuscular blocking activities of Lincomycin.,Taking Mecamylamine with Lincomycin can make muscle relaxation stronger than expected.
Atracurium besylate may increase the neuromuscular blocking activities of Lincomycin.,Atracurium besylate can cause stronger muscle-relaxing effects when combined with Lincomycin.
Mivacurium may increase the neuromuscular blocking activities of Lincomycin.,Mivacurium can make the muscle relaxation from Lincomycin more intense.
Succinylcholine may increase the neuromuscular blocking activities of Lincomycin.,Succinylcholine may boost the muscle-relaxing effects of Lincomycin.
Vecuronium may increase the neuromuscular blocking activities of Lincomycin.,Vecuronium can make Lincomycin's muscle relaxation stronger.
Pipecuronium may increase the neuromuscular blocking activities of Lincomycin.,Pipecuronium can increase the muscle-relaxing effect of Lincomycin.
Pancuronium may increase the neuromuscular blocking activities of Lincomycin.,Pancuronium may make Lincomycin's muscle-relaxing effects more powerful.
Gallamine triethiodide may increase the neuromuscular blocking activities of Lincomycin.,Gallamine triethiodide can cause stronger muscle relaxation when used with Lincomycin.
Tubocurarine may increase the neuromuscular blocking activities of Lincomycin.,Tubocurarine may lead to more intense muscle relaxation when taken with Lincomycin.
Cisatracurium may increase the neuromuscular blocking activities of Lincomycin.,Cisatracurium can enhance the muscle-relaxing impact of Lincomycin.
Pyrantel may increase the neuromuscular blocking activities of Lincomycin.,Pyrantel may make Lincomycin's muscle effects stronger.
Rocuronium may increase the neuromuscular blocking activities of Lincomycin.,Rocuronium can cause more powerful muscle relaxation when taken with Lincomycin.
Doxacurium may increase the neuromuscular blocking activities of Lincomycin.,Doxacurium may increase muscle weakness when combined with Lincomycin.
Metocurine may increase the neuromuscular blocking activities of Lincomycin.,Metocurine can boost Lincomycin’s muscle-relaxing properties.
Mecamylamine may increase the neuromuscular blocking activities of Polymyxin B.,Mecamylamine with Polymyxin B can lead to stronger muscle relaxation.
Atracurium besylate may increase the neuromuscular blocking activities of Polymyxin B.,Atracurium besylate may make muscle relaxation from Polymyxin B more intense.
Mivacurium may increase the neuromuscular blocking activities of Polymyxin B.,Mivacurium can increase the muscle-relaxing effects of Polymyxin B.
Succinylcholine may increase the neuromuscular blocking activities of Polymyxin B.,Succinylcholine may make Polymyxin B's muscle effects stronger.
Vecuronium may increase the neuromuscular blocking activities of Polymyxin B.,Vecuronium can cause extra muscle weakness when used with Polymyxin B.
Pipecuronium may increase the neuromuscular blocking activities of Polymyxin B.,Pipecuronium may increase how much Polymyxin B relaxes the muscles.
Pancuronium may increase the neuromuscular blocking activities of Polymyxin B.,Pancuronium can lead to stronger-than-expected muscle relaxation with Polymyxin B.
Gallamine triethiodide may increase the neuromuscular blocking activities of Polymyxin B.,Gallamine triethiodide may intensify muscle relaxation when taken with Polymyxin B.
Tubocurarine may increase the neuromuscular blocking activities of Polymyxin B.,Tubocurarine can boost the muscle-relaxing effects of Polymyxin B.
Cisatracurium may increase the neuromuscular blocking activities of Polymyxin B.,Cisatracurium may make muscle relaxation from Polymyxin B more powerful.
Pyrantel may increase the neuromuscular blocking activities of Polymyxin B.,Pyrantel can add to the muscle weakness caused by Polymyxin B.
Rocuronium may increase the neuromuscular blocking activities of Polymyxin B.,Rocuronium may increase the muscle-relaxing impact of Polymyxin B.
Doxacurium may increase the neuromuscular blocking activities of Polymyxin B.,Doxacurium can make Polymyxin B’s muscle effects stronger.
Metocurine may increase the neuromuscular blocking activities of Polymyxin B.,Metocurine may cause greater muscle relaxation when used with Polymyxin B.
Colistimethate may increase the neuromuscular blocking activities of Polymyxin B.,Colistimethate can intensify muscle relaxation from Polymyxin B
Metamfetamine may decrease the sedative activities of Isothipendyl.,Taking Metamfetamine with Isothipendyl may reduce how sleepy or relaxed you feel.
Pseudoephedrine may decrease the sedative activities of Isothipendyl.,Pseudoephedrine might make Isothipendyl less effective at causing drowsiness.
Mephentermine may decrease the sedative activities of Isothipendyl.,Mephentermine can make the calming effects of Isothipendyl weaker.
Amphetamine may decrease the sedative activities of Buclizine.,Amphetamine might reduce how sleepy Buclizine makes you feel.
Diethylpropion may decrease the sedative activities of Buclizine.,Diethylpropion can lower the sedative effect of Buclizine.
Phentermine may decrease the sedative activities of Buclizine.,Phentermine may make Buclizine less calming or drowsy.
Hydroxyamphetamine may decrease the sedative activities of Buclizine.,Hydroxyamphetamine might reduce the relaxing effects of Buclizine.
Lisdexamfetamine may decrease the sedative activities of Buclizine.,Lisdexamfetamine may make Buclizine less effective at causing drowsiness.
Dextroamphetamine may decrease the sedative activities of Buclizine.,Dextroamphetamine can decrease how sedated you feel from Buclizine.
Benzphetamine may decrease the sedative activities of Buclizine.,Benzphetamine may lessen the calming effect of Buclizine.
Metamfetamine may decrease the sedative activities of Buclizine.,Metamfetamine might reduce the sedative power of Buclizine.
Pseudoephedrine may decrease the sedative activities of Buclizine.,Pseudoephedrine could weaken the sleepy effects of Buclizine.
Mephentermine may decrease the sedative activities of Buclizine.,Mephentermine may make Buclizine less likely to cause drowsiness.
Amphetamine may decrease the sedative activities of Ketotifen.,Amphetamine can reduce how calming Ketotifen is.
Diethylpropion may decrease the sedative activities of Ketotifen.,Diethylpropion may make Ketotifen less sedating.
Phentermine may decrease the sedative activities of Ketotifen.,Phentermine could weaken the drowsy effects of Ketotifen.
Hydroxyamphetamine may decrease the sedative activities of Ketotifen.,Hydroxyamphetamine may make Ketotifen less calming.
Lisdexamfetamine may decrease the sedative activities of Ketotifen.,Lisdexamfetamine might reduce how sleepy Ketotifen makes you feel.
Dextroamphetamine may decrease the sedative activities of Ketotifen.,Dextroamphetamine can make the calming effects of Ketotifen weaker.
Benzphetamine may decrease the sedative activities of Ketotifen.,Benzphetamine may lower how sedating Ketotifen is.
Metamfetamine may decrease the sedative activities of Ketotifen.,Metamfetamine might make Ketotifen less effective at causing drowsiness.
Pseudoephedrine may decrease the sedative activities of Ketotifen.,Pseudoephedrine could reduce how relaxing Ketotifen feels.
Mephentermine may decrease the sedative activities of Ketotifen.,Mephentermine may make Ketotifen's sedative effects less noticeable.
Dextroamphetamine may decrease the sedative activities of Phenindamine.,Dextroamphetamine may make Phenindamine less sedating.
Benzphetamine may decrease the sedative activities of Phenindamine.,Benzphetamine might reduce how sleepy Phenindamine makes you feel.
Metamfetamine may decrease the sedative activities of Phenindamine.,Metamfetamine can lower the calming effects of Phenindamine.
Pseudoephedrine may decrease the sedative activities of Phenindamine.,Pseudoephedrine could make Phenindamine less likely to cause drowsiness.
Mephentermine may decrease the sedative activities of Phenindamine.,Mephentermine may decrease the sedative effects of Phenindamine.
Amphetamine may decrease the sedative activities of Alcaftadine.,Amphetamine might reduce how sleepy Alcaftadine makes you feel.
Diethylpropion may decrease the sedative activities of Alcaftadine.,Diethylpropion can make Alcaftadine less effective at causing drowsiness.
Phentermine may decrease the sedative activities of Alcaftadine.,Phentermine may weaken the calming effects of Alcaftadine.
Hydroxyamphetamine may decrease the sedative activities of Alcaftadine.,Hydroxyamphetamine might reduce Alcaftadine's sedative impact.
Lisdexamfetamine may decrease the sedative activities of Alcaftadine.,Lisdexamfetamine could lower the sleepy effects of Alcaftadine.
Dextroamphetamine may decrease the sedative activities of Alcaftadine.,Dextroamphetamine may reduce how relaxing Alcaftadine feels.
Benzphetamine may decrease the sedative activities of Alcaftadine.,Benzphetamine might make Alcaftadine less calming.
Metamfetamine may decrease the sedative activities of Alcaftadine.,Metamfetamine may decrease the drowsy effect of Alcaftadine.
Pseudoephedrine may decrease the sedative activities of Alcaftadine.,Pseudoephedrine can reduce how sedating Alcaftadine is.
Mephentermine may decrease the sedative activities of Alcaftadine.,Mephentermine may weaken the relaxing effects of Alcaftadine.
Amphetamine may decrease the sedative activities of Thonzylamine.,Amphetamine might make Thonzylamine less sedating.
Diethylpropion may decrease the sedative activities of Thonzylamine.,Diethylpropion can lower the calming effects of Thonzylamine.
Phentermine may decrease the sedative activities of Thonzylamine.,Phentermine may reduce how sleepy Thonzylamine makes you feel.
Hydroxyamphetamine may decrease the sedative activities of Thonzylamine.,Hydroxyamphetamine might make Thonzylamine less effective at causing drowsiness.
Lisdexamfetamine may decrease the sedative activities of Thonzylamine.,Lisdexamfetamine could decrease the sedative power of Thonzylamine.
Dextroamphetamine may decrease the sedative activities of Thonzylamine.,Dextroamphetamine may reduce the calming effects of Thonzylamine.
Benzphetamine may decrease the sedative activities of Thonzylamine.,Benzphetamine might make Thonzylamine less relaxing.
Metamfetamine may decrease the sedative activities of Thonzylamine.,Metamfetamine may weaken how sedating Thonzylamine is.
Pseudoephedrine may decrease the sedative activities of Thonzylamine.,Pseudoephedrine can reduce how sleepy Thonzylamine makes you feel.
Mephentermine may decrease the sedative activities of Thonzylamine.,Mephentermine may lower the calming effect of Thonzylamine.
Amphetamine may decrease the sedative activities of Alimemazine.,Amphetamine might make Alimemazine less effective at causing drowsiness.
Diethylpropion may decrease the sedative activities of Alimemazine.,Diethylpropion can weaken the sleepy effects of Alimemazine.
Phentermine may decrease the sedative activities of Alimemazine.,Phentermine may reduce how calming Alimemazine feels.
The serum concentration of Diethylpropion can be decreased when it is combined with Glutamic acid.,Diethylpropion may become less effective when taken with Glutamic acid.
Cyclosporine may increase the neurotoxic activities of Imipenem.,Cyclosporine can increase the risk of nerve-related side effects when taken with Imipenem.
The serum concentration of Acyclovir can be increased when it is combined with Tizanidine.,Tizanidine may raise the amount of Acyclovir in the blood.
The serum concentration of Obeticholic acid can be increased when it is combined with Tizanidine.,Tizanidine may increase the amount of Obeticholic acid in the blood.
The serum concentration of Piperazine can be decreased when it is combined with Primaquine.,Primaquine can lower the level of Piperazine in the body.
The serum concentration of Piperazine can be decreased when it is combined with Amodiaquine.,Amodiaquine may reduce the amount of Piperazine in the blood.
The serum concentration of Piperazine can be decreased when it is combined with Hydroxychloroquine.,Hydroxychloroquine may lower how much Piperazine is in the body.
The serum concentration of Phensuximide can be increased when it is combined with Cilostazol.,Cilostazol may raise the amount of Phensuximide in the blood.
The therapeutic efficacy of Phensuximide can be decreased when used in combination with Pregabalin.,Pregabalin may make Phensuximide work less effectively.
The therapeutic efficacy of Phensuximide can be decreased when used in combination with Mianserin.,Mianserin may reduce how well Phensuximide works.
The therapeutic efficacy of Phensuximide can be decreased when used in combination with Mefloquine.,Mefloquine may lower the effectiveness of Phensuximide.
The serum concentration of Phensuximide can be decreased when it is combined with Orlistat.,Orlistat may decrease the amount of Phensuximide in the body.
Amphetamine may decrease the sedative activities of Lodoxamide.,Amphetamine may make Lodoxamide less calming or drowsy.
Diethylpropion may decrease the sedative activities of Lodoxamide.,Diethylpropion can weaken the sedative effect of Lodoxamide.
Phentermine may decrease the sedative activities of Lodoxamide.,Phentermine might reduce how sleepy Lodoxamide makes you feel.
Hydroxyamphetamine may decrease the sedative activities of Lodoxamide.,Hydroxyamphetamine may decrease the relaxing effects of Lodoxamide.
Lisdexamfetamine may decrease the sedative activities of Lodoxamide.,Lisdexamfetamine could make Lodoxamide less sedating.
Dextroamphetamine may decrease the sedative activities of Lodoxamide.,Dextroamphetamine may reduce the calming effect of Lodoxamide.
Benzphetamine may decrease the sedative activities of Lodoxamide.,Benzphetamine might make Lodoxamide less effective at causing drowsiness.
Metamfetamine may decrease the sedative activities of Lodoxamide.,Metamfetamine may lower the sedative effects of Lodoxamide.
Pseudoephedrine may decrease the sedative activities of Lodoxamide.,Pseudoephedrine can make Lodoxamide's drowsy effect weaker.
Methadone may increase the analgesic activities of Diethylpropion.,Methadone may make Diethylpropion’s pain-relieving effects stronger.
Buprenorphine may increase the analgesic activities of Diethylpropion.,Buprenorphine can increase how well Diethylpropion relieves pain.
Butorphanol may increase the analgesic activities of Diethylpropion.,Butorphanol may boost the pain relief from Diethylpropion.
Hydrocodone may increase the analgesic activities of Diethylpropion.,Hydrocodone might make Diethylpropion more effective at easing pain.
Ethylmorphine may increase the analgesic activities of Diethylpropion.,Ethylmorphine may enhance Diethylpropion’s ability to reduce pain.
Tapentadol may increase the analgesic activities of Diethylpropion.,Tapentadol can make Diethylpropion’s pain relief stronger.
Hydromorphone may increase the analgesic activities of Diethylpropion.,Hydromorphone may improve how well Diethylpropion works for pain.
Dextropropoxyphene may increase the analgesic activities of Diethylpropion.,Dextropropoxyphene could increase the pain-relieving effects of Diethylpropion.
Levorphanol may increase the analgesic activities of Diethylpropion.,Levorphanol may strengthen the pain relief provided by Diethylpropion.
Fentanyl may increase the analgesic activities of Diethylpropion.,Fentanyl can boost how well Diethylpropion works against pain.
Meperidine may increase the analgesic activities of Diethylpropion.,Meperidine may enhance Diethylpropion’s ability to relieve pain.
Dezocine may increase the analgesic activities of Diethylpropion.,Dezocine could make Diethylpropion more effective at reducing pain.
Methadyl acetate may increase the analgesic activities of Diethylpropion.,Methadyl acetate may increase the pain-relieving strength of Diethylpropion.
Alfentanil may increase the analgesic activities of Diethylpropion.,Alfentanil can improve how Diethylpropion helps with pain.
Diamorphine may increase the analgesic activities of Diethylpropion.,Diamorphine may make the pain relief from Diethylpropion more intense.
Sufentanil may increase the analgesic activities of Diethylpropion.,Sufentanil can boost Diethylpropion’s pain-relieving power.
Normethadone may increase the analgesic activities of Diethylpropion.,Normethadone might increase how well Diethylpropion eases pain.
Nalbuphine may increase the analgesic activities of Diethylpropion.,Nalbuphine may strengthen Diethylpropion’s effects on pain.
Remifentanil may increase the analgesic activities of Diethylpropion.,Remifentanil could enhance Diethylpropion’s pain relief.
Oxycodone may increase the analgesic activities of Diethylpropion.,Oxycodone may increase the pain-relieving action of Diethylpropion.
Tramadol may increase the analgesic activities of Diethylpropion.,Tramadol can boost Diethylpropion’s ability to reduce pain.
Diphenoxylate may increase the analgesic activities of Diethylpropion.,Diphenoxylate may make Diethylpropion more effective at easing pain.
Oxymorphone may increase the analgesic activities of Diethylpropion.,Oxymorphone can enhance the pain relief effects of Diethylpropion.
Codeine may increase the analgesic activities of Diethylpropion.,Codeine might make Diethylpropion better at relieving pain.
Pentazocine may increase the analgesic activities of Diethylpropion.,Pentazocine may increase Diethylpropion’s pain-relieving effects.
Morphine may increase the analgesic activities of Diethylpropion.,Morphine can boost how much pain relief you get from Diethylpropion.
Dihydrocodeine may increase the analgesic activities of Diethylpropion.,Dihydrocodeine may strengthen the pain-relieving action of Diethylpropion.
Methadone may increase the analgesic activities of Lisdexamfetamine.,Methadone may make Lisdexamfetamine’s pain-relieving effects stronger.
Buprenorphine may increase the analgesic activities of Lisdexamfetamine.,Buprenorphine can increase how well Lisdexamfetamine helps with pain.
Butorphanol may increase the analgesic activities of Lisdexamfetamine.,Butorphanol might boost the pain relief from Lisdexamfetamine.
Hydrocodone may increase the analgesic activities of Lisdexamfetamine.,Hydrocodone may enhance Lisdexamfetamine’s ability to reduce pain.
Ethylmorphine may increase the analgesic activities of Lisdexamfetamine.,Ethylmorphine could increase the pain-relieving effects of Lisdexamfetamine.
Tapentadol may increase the analgesic activities of Lisdexamfetamine.,Tapentadol may make Lisdexamfetamine more effective for pain relief.
Hydromorphone may increase the analgesic activities of Lisdexamfetamine.,Hydromorphone can improve the pain relief from Lisdexamfetamine.
Dextropropoxyphene may increase the analgesic activities of Lisdexamfetamine.,Dextropropoxyphene may enhance Lisdexamfetamine’s effect on pain.
Levorphanol may increase the analgesic activities of Lisdexamfetamine.,Levorphanol might boost how well Lisdexamfetamine eases pain.
Fentanyl may increase the analgesic activities of Lisdexamfetamine.,Fentanyl can strengthen Lisdexamfetamine’s pain-relieving power.
Meperidine may increase the analgesic activities of Lisdexamfetamine.,Meperidine may make Lisdexamfetamine more effective at relieving pain.
Dezocine may increase the analgesic activities of Lisdexamfetamine.,Dezocine can increase the pain-relieving activity of Lisdexamfetamine.
Methadyl acetate may increase the analgesic activities of Lisdexamfetamine.,Methadyl acetate might enhance how Lisdexamfetamine helps with pain.
Alfentanil may increase the analgesic activities of Lisdexamfetamine.,Alfentanil may increase the pain relief effects of Lisdexamfetamine.
Diamorphine may increase the analgesic activities of Lisdexamfetamine.,Diamorphine could boost how well Lisdexamfetamine eases pain.
Sufentanil may increase the analgesic activities of Lisdexamfetamine.,Sufentanil can make Lisdexamfetamine more effective for pain relief.
Normethadone may increase the analgesic activities of Lisdexamfetamine.,Normethadone may enhance the pain-relieving properties of Lisdexamfetamine.
Nalbuphine may increase the analgesic activities of Lisdexamfetamine.,Nalbuphine might strengthen Lisdexamfetamine’s pain relief.
Remifentanil may increase the analgesic activities of Lisdexamfetamine.,Remifentanil may increase how much pain relief Lisdexamfetamine provides.
Oxycodone may increase the analgesic activities of Lisdexamfetamine.,Oxycodone can make Lisdexamfetamine more effective against pain.
Tramadol may increase the analgesic activities of Lisdexamfetamine.,Tramadol may boost the pain-relieving effects of Lisdexamfetamine.
Diphenoxylate may increase the analgesic activities of Lisdexamfetamine.,Diphenoxylate might enhance how well Lisdexamfetamine works for pain.
Oxymorphone may increase the analgesic activities of Lisdexamfetamine.,Oxymorphone can increase the strength of Lisdexamfetamine’s pain relief.
Codeine may increase the analgesic activities of Lisdexamfetamine.,Codeine may make Lisdexamfetamine better at relieving pain.
Pentazocine may increase the analgesic activities of Lisdexamfetamine.,Pentazocine might boost Lisdexamfetamine’s effects on pain.
Morphine may increase the analgesic activities of Lisdexamfetamine.,Morphine can strengthen the pain relief from Lisdexamfetamine.
Dihydrocodeine may increase the analgesic activities of Lisdexamfetamine.,Dihydrocodeine may make Lisdexamfetamine more effective at reducing pain.
The serum concentration of Lisdexamfetamine can be decreased when it is combined with Guanethidine.,"Guanethidine may lower the amount of Lisdexamfetamine in the blood, reducing its effects."
Ioflupane I-123 may decrease effectiveness of Lisdexamfetamine as a diagnostic agent.,Ioflupane I-123 might interfere with how well Lisdexamfetamine works as a diagnostic tool.
The serum concentration of Cefditoren can be decreased when it is combined with Roxatidine acetate.,Roxatidine acetate may reduce how much Cefditoren is absorbed into the body.
The serum concentration of Cefditoren can be decreased when it is combined with Nizatidine.,Nizatidine can lower the amount of Cefditoren in the blood.
The serum concentration of Lactic acid can be increased when it is combined with Flecainide.,Flecainide may increase the amount of Lactic acid in the body.
The serum concentration of Ertapenem can be increased when it is combined with Tacrolimus.,Tacrolimus can raise the level of Ertapenem in the blood.
The serum concentration of Rifaximin can be increased when it is combined with Pitavastatin.,Pitavastatin may increase the amount of Rifaximin in the bloodstream.
Isoniazid may increase the hepatotoxic activities of Rifaximin.,Isoniazid might make Rifaximin more harmful to the liver.
The serum concentration of Rifapentine can be increased when it is combined with Pitavastatin.,Pitavastatin can raise the level of Rifapentine in the blood.
Isoniazid may increase the hepatotoxic activities of Rifapentine.,Isoniazid may increase the risk of liver damage from Rifapentine.
The serum concentration of Rifapentine can be increased when it is combined with Raltegravir.,Raltegravir may increase how much Rifapentine is in the body.
The risk or severity of adverse effects can be increased when Methadone is combined with Alvimopan.,Taking Methadone with Alvimopan may increase the chance of side effects.
The risk or severity of adverse effects can be increased when Buprenorphine is combined with Alvimopan.,Buprenorphine combined with Alvimopan can raise the risk of unwanted side effects.
The risk or severity of adverse effects can be increased when Butorphanol is combined with Alvimopan.,Butorphanol and Alvimopan together may lead to stronger side effects.
The risk or severity of adverse effects can be increased when Hydrocodone is combined with Alvimopan.,Hydrocodone may increase the risk of side effects when used with Alvimopan.
The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Alvimopan.,Ethylmorphine taken with Alvimopan can raise the chance of negative effects.
The serum concentration of Lanthanum carbonate can be decreased when it is combined with Pitavastatin.,Lanthanum carbonate's concentration in the blood is lower when taken with Pitavastatin.
The serum concentration of Lanthanum carbonate can be decreased when it is combined with Fluvastatin.,Lanthanum carbonate's concentration in the blood is lower when taken with Fluvastatin.
The serum concentration of Lanthanum carbonate can be decreased when it is combined with Rosuvastatin.,Lanthanum carbonate's concentration in the blood is lower when taken with Rosuvastatin.
The serum concentration of Lanthanum carbonate can be decreased when it is combined with Atorvastatin.,Lanthanum carbonate's concentration in the blood is lower when taken with Atorvastatin.
The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Amiodarone.,Iodide I-131's effectiveness in treating thyroid problems is reduced when taken with Amiodarone.
The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Methimazole.,Iodide I-131's effectiveness in treating thyroid problems is reduced when taken with Methimazole.
The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Carbimazole.,Iodide I-131's effectiveness in treating thyroid problems is reduced when taken with Carbimazole.
The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Liothyronine.,Iodide I-131's effectiveness in treating thyroid problems is reduced when taken with Liothyronine.
The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Levothyroxine.,Iodide I-131's effectiveness in treating thyroid problems is reduced when taken with Levothyroxine.
The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Propylthiouracil.,Iodide I-131's effectiveness in treating thyroid problems is reduced when taken with Propylthiouracil.
The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Potassium Iodide.,Iodide I-131's effectiveness in treating thyroid problems is reduced when taken with Potassium Iodide.
The therapeutic efficacy of Cysteamine can be decreased when used in combination with Asenapine.,Cysteamine's effectiveness in treating certain genetic disorders is reduced when taken with Asenapine.
The therapeutic efficacy of Cysteamine can be decreased when used in combination with Bismuth subcitrate potassium.,Cysteamine's effectiveness in treating certain genetic disorders is reduced when taken with Bismuth subcitrate potassium.
The therapeutic efficacy of Cysteamine can be decreased when used in combination with Tromethamine.,Cysteamine's effectiveness in treating certain genetic disorders is reduced when taken with Tromethamine.
The therapeutic efficacy of Cysteamine can be decreased when used in combination with Aluminium.,Cysteamine's effectiveness in treating certain genetic disorders is reduced when taken with Aluminium.
The therapeutic efficacy of Cysteamine can be decreased when used in combination with Magnesium hydroxide.,Cysteamine's effectiveness in treating certain genetic disorders is reduced when taken with Magnesium hydroxide.
The therapeutic efficacy of Cysteamine can be decreased when used in combination with Calcium carbonate.,Cysteamine's effectiveness in treating certain genetic disorders is reduced when taken with Calcium carbonate.
Profenamine may increase the ulcerogenic activities of Potassium chloride.,Profenamine may increase the risk of ulcers when taken with Potassium chloride.
Biperiden may increase the ulcerogenic activities of Potassium chloride.,Biperiden may increase the risk of ulcers when taken with Potassium chloride.
Cyclopentolate may increase the ulcerogenic activities of Potassium chloride.,Cyclopentolate may increase the risk of ulcers when taken with Potassium chloride.
Trospium may increase the ulcerogenic activities of Potassium chloride.,Trospium may increase the risk of ulcers when taken with Potassium chloride.
Atropine may increase the ulcerogenic activities of Potassium chloride.,Atropine may increase the risk of ulcers when taken with Potassium chloride.
Metixene may increase the ulcerogenic activities of Potassium chloride.,Metixene may increase the risk of ulcers when taken with Potassium chloride.
Propiverine may increase the ulcerogenic activities of Potassium chloride.,Propiverine may increase the risk of ulcers when taken with Potassium chloride.
Butylscopolamine may increase the ulcerogenic activities of Potassium chloride.,Butylscopolamine may increase the risk of ulcers when taken with Potassium chloride.
Methscopolamine may increase the ulcerogenic activities of Potassium chloride.,Methscopolamine may increase the risk of ulcers when taken with Potassium chloride.
Methscopolamine bromide may increase the ulcerogenic activities of Potassium chloride.,Methscopolamine bromide may increase the risk of ulcers when taken with Potassium chloride.
Ubidecarenone may increase the myopathic rhabdomyolysis activities of Acipimox.,Ubidecarenone may increase the risk of muscle damage (rhabdomyolysis) when taken with Acipimox.
Lovastatin may increase the myopathic rhabdomyolysis activities of Acipimox.,Lovastatin may increase the risk of muscle damage (rhabdomyolysis) when taken with Acipimox.
Pravastatin may increase the myopathic rhabdomyolysis activities of Acipimox.,Pravastatin may increase the risk of muscle damage (rhabdomyolysis) when taken with Acipimox.
Simvastatin may increase the myopathic rhabdomyolysis activities of Acipimox.,Simvastatin may increase the risk of muscle damage (rhabdomyolysis) when taken with Acipimox.
Pitavastatin may increase the myopathic rhabdomyolysis activities of Acipimox.,Pitavastatin may increase the risk of muscle damage (rhabdomyolysis) when taken with Acipimox.
Fluvastatin may increase the myopathic rhabdomyolysis activities of Acipimox.,Fluvastatin may increase the risk of muscle damage (rhabdomyolysis) when taken with Acipimox.
Rosuvastatin may increase the myopathic rhabdomyolysis activities of Acipimox.,Rosuvastatin may increase the risk of muscle damage (rhabdomyolysis) when taken with Acipimox.
Atorvastatin may increase the myopathic rhabdomyolysis activities of Acipimox.,Atorvastatin may increase the risk of muscle damage (rhabdomyolysis) when taken with Acipimox.
Clofibrate may increase the myopathic rhabdomyolysis activities of Acipimox.,Clofibrate may increase the risk of muscle damage (rhabdomyolysis) when taken with Acipimox.
Bezafibrate may increase the myopathic rhabdomyolysis activities of Acipimox.,Bezafibrate may increase the risk of muscle damage (rhabdomyolysis) when taken with Acipimox.
Fenofibrate may increase the myopathic rhabdomyolysis activities of Acipimox.,Fenofibrate may increase the risk of muscle damage (rhabdomyolysis) when taken with Acipimox.
Gemfibrozil may increase the myopathic rhabdomyolysis activities of Acipimox.,Gemfibrozil may increase the risk of muscle damage (rhabdomyolysis) when taken with Acipimox.
Etofibrate may increase the myopathic rhabdomyolysis activities of Acipimox.,Etofibrate may increase the risk of muscle damage (rhabdomyolysis) when taken with Acipimox.
Fenofibric acid may increase the myopathic rhabdomyolysis activities of Acipimox.,Fenofibric acid may increase the risk of muscle damage (rhabdomyolysis) when taken with Acipimox.
The risk or severity of adverse effects can be increased when Ubidecarenone is combined with Daptomycin.,The risk or severity of side effects can be increased when Ubidecarenone is taken with Daptomycin.
The risk or severity of adverse effects can be increased when Lovastatin is combined with Daptomycin.,The risk or severity of side effects can be increased when Lovastatin is taken with Daptomycin.
The risk or severity of adverse effects can be increased when Pravastatin is combined with Daptomycin.,The risk or severity of side effects can be increased when Pravastatin is taken with Daptomycin.
The risk or severity of adverse effects can be increased when Simvastatin is combined with Daptomycin.,The risk or severity of side effects can be increased when Simvastatin is taken with Daptomycin.
Pancuronium may increase the constipating activities of Eluxadoline.,Pancuronium may increase the risk of constipation when taken with Eluxadoline.
Gallamine triethiodide may increase the constipating activities of Eluxadoline.,Gallamine triethiodide may increase the risk of constipation when taken with Eluxadoline.
Tubocurarine may increase the constipating activities of Eluxadoline.,Tubocurarine may increase the risk of constipation when taken with Eluxadoline.
Scopolamine may increase the constipating activities of Eluxadoline.,Scopolamine may increase the risk of constipation when taken with Eluxadoline.
Desloratadine may increase the constipating activities of Eluxadoline.,Desloratadine may increase the risk of constipation when taken with Eluxadoline.
Aclidinium may increase the constipating activities of Eluxadoline.,Aclidinium may increase the risk of constipation when taken with Eluxadoline.
Pirenzepine may increase the constipating activities of Eluxadoline.,Pirenzepine may increase the risk of constipation when taken with Eluxadoline.
Anisotropine methylbromide may increase the constipating activities of Eluxadoline.,Anisotropine methylbromide may increase the risk of constipation when taken with Eluxadoline.
Procyclidine may increase the constipating activities of Eluxadoline.,Procyclidine may increase the risk of constipation when taken with Eluxadoline.
Propantheline may increase the constipating activities of Eluxadoline.,Propantheline may increase the risk of constipation when taken with Eluxadoline.
Oxyphenonium may increase the constipating activities of Eluxadoline.,Oxyphenonium may increase the risk of constipation when taken with Eluxadoline.
Hyoscyamine may increase the constipating activities of Eluxadoline.,Hyoscyamine may increase the risk of constipation when taken with Eluxadoline.
Trihexyphenidyl may increase the constipating activities of Eluxadoline.,Trihexyphenidyl may increase the risk of constipation when taken with Eluxadoline.
Tropicamide may increase the constipating activities of Eluxadoline.,Tropicamide may increase the risk of constipation when taken with Eluxadoline.
Dicyclomine may increase the constipating activities of Eluxadoline.,Dicyclomine may increase the risk of constipation when taken with Eluxadoline.
Profenamine may increase the constipating activities of Eluxadoline.,Profenamine may increase the risk of constipation when taken with Eluxadoline.
Biperiden may increase the constipating activities of Eluxadoline.,Biperiden may increase the risk of constipation when taken with Eluxadoline.
Cyclopentolate may increase the constipating activities of Eluxadoline.,Cyclopentolate may increase the risk of constipation when taken with Eluxadoline.
Trospium may increase the constipating activities of Eluxadoline.,Trospium may increase the risk of constipation when taken with Eluxadoline.
Atropine may increase the constipating activities of Eluxadoline.,Atropine may increase the risk of constipation when taken with Eluxadoline.
Metixene may increase the constipating activities of Eluxadoline.,Metixene may increase the risk of constipation when taken with Eluxadoline.
Propiverine may increase the constipating activities of Eluxadoline.,Propiverine may increase the risk of constipation when taken with Eluxadoline.
Butylscopolamine may increase the constipating activities of Eluxadoline.,Butylscopolamine may increase the risk of constipation when taken with Eluxadoline.
Methscopolamine may increase the constipating activities of Eluxadoline.,Methscopolamine may increase the risk of constipation when taken with Eluxadoline.
Methscopolamine bromide may increase the constipating activities of Eluxadoline.,Methscopolamine bromide may increase the risk of constipation when taken with Eluxadoline.
Quinidine may increase the ulcerogenic activities of Potassium chloride.,Quinidine may increase the risk of ulcers when taken with Potassium chloride.
The serum concentration of Cefdinir can be decreased when it is combined with Iron sucrose.,The serum concentration of Cefdinir can be lower when taken with Iron sucrose.
The serum concentration of Cefdinir can be decreased when it is combined with Iron.,The serum concentration of Cefdinir can be lower when taken with Iron.
The serum concentration of Cefdinir can be decreased when it is combined with Ferric pyrophosphate.,The serum concentration of Cefdinir can be lower when taken with Ferric pyrophosphate.
Quinidine may increase the constipating activities of Eluxadoline.,Quinidine may increase the risk of constipation when taken with Eluxadoline.
The serum concentration of Eluxadoline can be increased when it is combined with Rosuvastatin.,The serum concentration of Eluxadoline can be higher when taken with Rosuvastatin.
Methadone may increase the constipating activities of Eluxadoline.,Methadone may increase the risk of constipation when taken with Eluxadoline.
Trimethaphan may increase the constipating activities of Eluxadoline.,Trimethaphan may increase the risk of constipation when taken with Eluxadoline.
Buprenorphine may increase the constipating activities of Eluxadoline.,Buprenorphine may increase the risk of constipation when taken with Eluxadoline.
Butorphanol may increase the constipating activities of Eluxadoline.,Butorphanol may increase the risk of constipation when taken with Eluxadoline.
Hydrocodone may increase the constipating activities of Eluxadoline.,Hydrocodone may increase the risk of constipation when taken with Eluxadoline.
Ethylmorphine may increase the constipating activities of Eluxadoline.,Ethylmorphine may increase the risk of constipation when taken with Eluxadoline.
Tapentadol may increase the constipating activities of Eluxadoline.,Tapentadol may increase the risk of constipation when taken with Eluxadoline.
Hydromorphone may increase the constipating activities of Eluxadoline.,Hydromorphone may increase the risk of constipation when taken with Eluxadoline.
Dextropropoxyphene may increase the constipating activities of Eluxadoline.,Dextropropoxyphene may increase the risk of constipation when taken with Eluxadoline.
Levorphanol may increase the constipating activities of Eluxadoline.,Levorphanol may increase the risk of constipation when taken with Eluxadoline.
Fentanyl may increase the constipating activities of Eluxadoline.,Fentanyl may increase the risk of constipation when taken with Eluxadoline.
Meperidine may increase the constipating activities of Eluxadoline.,Meperidine may increase the risk of constipation when taken with Eluxadoline.
Dezocine may increase the constipating activities of Eluxadoline.,Dezocine may increase the risk of constipation when taken with Eluxadoline.
Methadyl acetate may increase the constipating activities of Eluxadoline.,Methadyl acetate may increase the risk of constipation when taken with Eluxadoline.
Alfentanil may increase the constipating activities of Eluxadoline.,Alfentanil may increase the risk of constipation when taken with Eluxadoline.
Diamorphine may increase the constipating activities of Eluxadoline.,Diamorphine may increase the risk of constipation when taken with Eluxadoline.
Sufentanil may increase the constipating activities of Eluxadoline.,Sufentanil may increase the risk of constipation when taken with Eluxadoline.
Normethadone may increase the constipating activities of Eluxadoline.,Normethadone may increase the risk of constipation when taken with Eluxadoline.
Nalbuphine may increase the constipating activities of Eluxadoline.,Nalbuphine may increase the risk of constipation when taken with Eluxadoline.
Remifentanil may increase the constipating activities of Eluxadoline.,Remifentanil may increase the risk of constipation when taken with Eluxadoline.
Oxycodone may increase the constipating activities of Eluxadoline.,Oxycodone may increase the risk of constipation when taken with Eluxadoline.
Tramadol may increase the constipating activities of Eluxadoline.,Tramadol may increase the risk of constipation when taken with Eluxadoline.
Diphenoxylate may increase the constipating activities of Eluxadoline.,Diphenoxylate may increase the risk of constipation when taken with Eluxadoline.
Oxymorphone may increase the constipating activities of Eluxadoline.,Oxymorphone may increase the risk of constipation when taken with Eluxadoline.
Codeine may increase the constipating activities of Eluxadoline.,Codeine may increase the risk of constipation when taken with Eluxadoline.
Pentazocine may increase the constipating activities of Eluxadoline.,Pentazocine may increase the risk of constipation when taken with Eluxadoline.
Morphine may increase the constipating activities of Eluxadoline.,Morphine may increase the risk of constipation when taken with Eluxadoline.
Dihydrocodeine may increase the constipating activities of Eluxadoline.,Dihydrocodeine may increase the risk of constipation when taken with Eluxadoline.
Mecamylamine may increase the constipating activities of Eluxadoline.,Mecamylamine may increase the risk of constipation when taken with Eluxadoline.
Atracurium besylate may increase the constipating activities of Eluxadoline.,Atracurium besylate may increase the risk of constipation when taken with Eluxadoline.
Orphenadrine may increase the constipating activities of Eluxadoline.,Orphenadrine may increase the risk of constipation when taken with Eluxadoline.
The risk or severity of adverse effects can be increased when Ethanol is combined with Eluxadoline.,The risk of side effects can be increased when Ethanol is taken with Eluxadoline.
Umeclidinium may increase the constipating activities of Eluxadoline.,Umeclidinium may increase the risk of constipation when taken with Eluxadoline.
Tiotropium may increase the constipating activities of Eluxadoline.,Tiotropium may increase the risk of constipation when taken with Eluxadoline.
Glycopyrronium may increase the constipating activities of Eluxadoline.,Glycopyrronium may increase the risk of constipation when taken with Eluxadoline.
Ipratropium may increase the constipating activities of Eluxadoline.,Ipratropium may increase the risk of constipation when taken with Eluxadoline.
Benzatropine may increase the constipating activities of Eluxadoline.,Benzatropine may increase the risk of constipation when taken with Eluxadoline.
Alosetron may increase the constipating activities of Eluxadoline.,Alosetron may increase the risk of constipation when taken with Eluxadoline.
Methantheline may increase the constipating activities of Eluxadoline.,Methantheline may increase the risk of constipation when taken with Eluxadoline.
Tolterodine may increase the constipating activities of Eluxadoline.,Tolterodine may increase the risk of constipation when taken with Eluxadoline.
Darifenacin may increase the constipating activities of Eluxadoline.,Darifenacin may increase the risk of constipation when taken with Eluxadoline.
Oxybutynin may increase the constipating activities of Eluxadoline.,Oxybutynin may increase the risk of constipation when taken with Eluxadoline.
Fesoterodine may increase the constipating activities of Eluxadoline.,Fesoterodine may increase the risk of constipation when taken with Eluxadoline.
The risk or severity of adverse effects can be increased when Tramadol is combined with Potassium cation.,The risk of side effects can be increased when Tramadol is taken with Potassium cation.
The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Potassium cation.,The risk of side effects can be increased when Diphenoxylate is taken with Potassium cation.
The risk or severity of adverse effects can be increased when Oxymorphone is combined with Potassium cation.,The risk of side effects can be increased when Oxymorphone is taken with Potassium cation.
The risk or severity of adverse effects can be increased when Codeine is combined with Potassium cation.,The risk of side effects can be increased when Codeine is taken with Potassium cation.
The risk or severity of adverse effects can be increased when Pentazocine is combined with Potassium cation.,The risk of side effects can be increased when Pentazocine is taken with Potassium cation.
The risk or severity of adverse effects can be increased when Morphine is combined with Potassium cation.,The risk of side effects can be increased when Morphine is taken with Potassium cation.
The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Potassium cation.,The risk of side effects can be increased when Dihydrocodeine is taken with Potassium cation.
The risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Potassium cation.,The risk of low blood pressure (hypotension) can be increased when Candesartan cilexetil is taken with Potassium cation.
"Sodium phosphate, monobasic may increase the nephrotoxic activities of Potassium cation.","Sodium phosphate, monobasic may increase the risk of kidney damage (nephrotoxicity) when taken with Potassium cation."
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Phenylalanine.,The risk of side effects can be increased when Pimecrolimus is taken with Phenylalanine.
The risk or severity of adverse effects can be increased when Tacrolimus is combined with Phenylalanine.,The risk of side effects can be increased when Tacrolimus is taken with Phenylalanine.
Roflumilast may increase the immunosuppressive activities of Phenylalanine.,Roflumilast may increase the immune-suppressing effect of Phenylalanine.
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Stepronin.,The risk of side effects can be increased when Pimecrolimus is taken with Stepronin.
The risk or severity of adverse effects can be increased when Tacrolimus is combined with Stepronin.,The risk of side effects can be increased when Tacrolimus is taken with Stepronin.
Roflumilast may increase the immunosuppressive activities of Stepronin.,Roflumilast may increase the immune-suppressing effect of Stepronin.
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benznidazole.,The risk of side effects can be increased when Pimecrolimus is taken with Benznidazole.
The risk or severity of adverse effects can be increased when Tacrolimus is combined with Benznidazole.,The risk of side effects can be increased when Tacrolimus is taken with Benznidazole.
Roflumilast may increase the immunosuppressive activities of Benznidazole.,Roflumilast may increase the immune-suppressing effect of Benznidazole.
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dimethyl fumarate.,The risk of side effects can be increased when Pimecrolimus is taken with Dimethyl fumarate.
The risk or severity of adverse effects can be increased when Tacrolimus is combined with Dimethyl fumarate.,The risk of side effects can be increased when Tacrolimus is taken with Dimethyl fumarate.
Roflumilast may increase the immunosuppressive activities of Dimethyl fumarate.,Roflumilast may increase the immune-suppressing effect of Dimethyl fumarate.
Glyburide may increase the hypoglycemic activities of Aminosalicylic acid.,Glyburide may increase the blood sugar-lowering effect of Aminosalicylic acid.
Bromocriptine may increase the hypoglycemic activities of Aminosalicylic acid.,Bromocriptine may increase the blood sugar-lowering effect of Aminosalicylic acid.
Quinapril may decrease the antihypertensive activities of Aminosalicylic acid.,Quinapril may reduce the blood pressure-lowering effect of Aminosalicylic acid.
Trolamine salicylate may increase the anticoagulant activities of Aminosalicylic acid.,Trolamine salicylate may increase the blood-thinning effect of Aminosalicylic acid.
The risk or severity of adverse effects can be increased when Cilostazol is combined with Aminosalicylic acid.,The risk of side effects can be increased when Cilostazol is taken with Aminosalicylic acid.
Methyl salicylate may increase the anticoagulant activities of Aminosalicylic acid.,Methyl salicylate may increase the blood-thinning effect of Aminosalicylic acid.
The risk or severity of adverse effects can be increased when Iloprost is combined with Aminosalicylic acid.,The risk of side effects can be increased when Iloprost is taken with Aminosalicylic acid.
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Aminosalicylic acid.,The risk of side effects can be increased when Sevoflurane is taken with Aminosalicylic acid.
The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Aminosalicylic acid.,The risk of side effects can be increased when Pentoxifylline is taken with Aminosalicylic acid.
Ramipril may decrease the antihypertensive activities of Aminosalicylic acid.,Ramipril may reduce the blood pressure-lowering effect of Aminosalicylic acid.
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Aminosalicylic acid.,The risk of side effects can be increased when Epoprostenol is taken with Aminosalicylic acid.
Moexipril may decrease the antihypertensive activities of Aminosalicylic acid.,Moexipril may reduce the blood pressure-lowering effect of Aminosalicylic acid.
Lisinopril may decrease the antihypertensive activities of Aminosalicylic acid.,Lisinopril may reduce the blood pressure-lowering effect of Aminosalicylic acid.
Enalapril may decrease the antihypertensive activities of Aminosalicylic acid.,Enalapril may reduce the blood pressure-lowering effect of Aminosalicylic acid.
Fosinopril may decrease the antihypertensive activities of Aminosalicylic acid.,Fosinopril may reduce the blood pressure-lowering effect of Aminosalicylic acid.
Trandolapril may decrease the antihypertensive activities of Aminosalicylic acid.,Trandolapril may reduce the blood pressure-lowering effect of Aminosalicylic acid.
Perindopril may decrease the antihypertensive activities of Aminosalicylic acid.,Perindopril may reduce the blood pressure-lowering effect of Aminosalicylic acid.
Benazepril may decrease the antihypertensive activities of Aminosalicylic acid.,Benazepril may reduce the blood pressure-lowering effect of Aminosalicylic acid.
Apixaban may increase the anticoagulant activities of Aminosalicylic acid.,Apixaban may increase the blood-thinning effect of Aminosalicylic acid.
Rivaroxaban may increase the anticoagulant activities of Aminosalicylic acid.,Rivaroxaban may increase the blood-thinning effect of Aminosalicylic acid.
The risk or severity of adverse effects can be increased when Argatroban is combined with Aminosalicylic acid.,The risk of side effects can be increased when Argatroban is taken with Aminosalicylic acid.
Bivalirudin may increase the anticoagulant activities of Aminosalicylic acid.,Bivalirudin may increase the blood-thinning effect of Aminosalicylic acid.
Dabigatran etexilate may increase the anticoagulant activities of Aminosalicylic acid.,Dabigatran etexilate may increase the blood-thinning effect of Aminosalicylic acid.
Edetic acid may increase the anticoagulant activities of Aminosalicylic acid.,Edetic acid may increase the blood-thinning effect of Aminosalicylic acid.
Fondaparinux may increase the anticoagulant activities of Aminosalicylic acid.,Fondaparinux may increase the blood-thinning effect of Aminosalicylic acid.
Pentaerythritol tetranitrate may increase the anticoagulant activities of Aminosalicylic acid.,Pentaerythritol tetranitrate may increase the blood-thinning effect of Aminosalicylic acid.
Citric acid may increase the anticoagulant activities of Aminosalicylic acid.,Citric acid may increase the blood-thinning effect of Aminosalicylic acid.
Pentosan polysulfate may increase the anticoagulant activities of Aminosalicylic acid.,Pentosan polysulfate may increase the blood-thinning effect of Aminosalicylic acid.
Protocatechualdehyde may increase the anticoagulant activities of Aminosalicylic acid.,Protocatechualdehyde may increase the blood-thinning effect of Aminosalicylic acid.
Cilazapril may decrease the antihypertensive activities of Aminosalicylic acid.,Cilazapril may reduce the blood pressure-lowering effect of Aminosalicylic acid.
Enalaprilat may decrease the antihypertensive activities of Aminosalicylic acid.,Enalaprilat may reduce the blood pressure-lowering effect of Aminosalicylic acid.
Captopril may decrease the antihypertensive activities of Aminosalicylic acid.,Captopril may reduce the blood pressure-lowering effect of Aminosalicylic acid.
Edetic acid may increase the anticoagulant activities of Trolamine salicylate.,Edetic acid may increase the blood-thinning effect of Trolamine salicylate.
Fondaparinux may increase the anticoagulant activities of Trolamine salicylate.,Fondaparinux may increase the blood-thinning effect of Trolamine salicylate.
Pentaerythritol tetranitrate may increase the anticoagulant activities of Trolamine salicylate.,Pentaerythritol tetranitrate may increase the blood-thinning effect of Trolamine salicylate.
Citric acid may increase the anticoagulant activities of Trolamine salicylate.,Citric acid may increase the blood-thinning effect of Trolamine salicylate.
Pentosan polysulfate may increase the anticoagulant activities of Trolamine salicylate.,Pentosan polysulfate may increase the blood-thinning effect of Trolamine salicylate.
Protocatechualdehyde may increase the anticoagulant activities of Trolamine salicylate.,Protocatechualdehyde may increase the blood-thinning effect of Trolamine salicylate.
Cilazapril may decrease the antihypertensive activities of Trolamine salicylate.,Cilazapril may reduce the blood pressure-lowering effect of Trolamine salicylate.
Enalaprilat may decrease the antihypertensive activities of Trolamine salicylate.,Enalaprilat may reduce the blood pressure-lowering effect of Trolamine salicylate.
Captopril may decrease the antihypertensive activities of Trolamine salicylate.,Captopril may reduce the blood pressure-lowering effect of Trolamine salicylate.
Rescinnamine may decrease the antihypertensive activities of Trolamine salicylate.,Rescinnamine may reduce the blood pressure-lowering effect of Trolamine salicylate.
Spirapril may decrease the antihypertensive activities of Trolamine salicylate.,Spirapril may reduce the blood pressure-lowering effect of Trolamine salicylate.
The risk or severity of adverse effects can be increased when Treprostinil is combined with Trolamine salicylate.,The risk of side effects can be increased when Treprostinil is taken with Trolamine salicylate.
The risk or severity of adverse effects can be increased when Dipyridamole is combined with Trolamine salicylate.,The risk of side effects can be increased when Dipyridamole is taken with Trolamine salicylate.
The risk or severity of adverse effects can be increased when Cangrelor is combined with Trolamine salicylate.,The risk of side effects can be increased when Cangrelor is taken with Trolamine salicylate.
The risk or severity of adverse effects can be increased when Ticlopidine is combined with Trolamine salicylate.,The risk of side effects can be increased when Ticlopidine is taken with Trolamine salicylate.
The risk or severity of adverse effects can be increased when Tirofiban is combined with Trolamine salicylate.,The risk of side effects can be increased when Tirofiban is taken with Trolamine salicylate.
The risk or severity of adverse effects can be increased when Triflusal is combined with Trolamine salicylate.,The risk of side effects can be increased when Triflusal is taken with Trolamine salicylate.
The risk or severity of adverse effects can be increased when Ticagrelor is combined with Trolamine salicylate.,The risk of side effects can be increased when Ticagrelor is taken with Trolamine salicylate.
The risk or severity of adverse effects can be increased when Vorapaxar is combined with Trolamine salicylate.,The risk of side effects can be increased when Vorapaxar is taken with Trolamine salicylate.
The risk or severity of adverse effects can be increased when Prasugrel is combined with Trolamine salicylate.,The risk of side effects can be increased when Prasugrel is taken with Trolamine salicylate.
The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Trolamine salicylate.,The risk of side effects can be increased when Icosapent ethyl is taken with Trolamine salicylate.
The risk or severity of adverse effects can be increased when Trapidil is combined with Trolamine salicylate.,The risk of side effects can be increased when Trapidil is taken with Trolamine salicylate.
The risk or severity of adverse effects can be increased when Ifenprodil is combined with Trolamine salicylate.,The risk of side effects can be increased when Ifenprodil is taken with Trolamine salicylate.
The risk or severity of adverse effects can be increased when Clopidogrel is combined with Trolamine salicylate.,The risk of side effects can be increased when Clopidogrel is taken with Trolamine salicylate.
The serum concentration of Trolamine salicylate can be increased when it is combined with Valproic acid.,The serum concentration of Trolamine salicylate can be increased when it is combined with Valproic acid.
The risk or severity of adverse effects can be increased when Epinastine is combined with Trolamine salicylate.,The risk of side effects can be increased when Epinastine is taken with Trolamine salicylate.
The risk or severity of adverse effects can be increased when Milrinone is combined with Trolamine salicylate.,The risk of side effects can be increased when Milrinone is taken with Trolamine salicylate.
The risk or severity of adverse effects can be increased when Alprostadil is combined with Trolamine salicylate.,The risk of side effects can be increased when Alprostadil is taken with Trolamine salicylate.
Edoxaban may increase the anticoagulant activities of Aminosalicylic acid.,Edoxaban may increase the blood-thinning effect of Aminosalicylic acid.
The risk or severity of adverse effects can be increased when Anagrelide is combined with Aminosalicylic acid.,The risk of side effects can be increased when Anagrelide is taken with Aminosalicylic acid.
Acarbose may increase the hypoglycemic activities of Aminosalicylic acid.,Acarbose may increase the blood sugar-lowering effect of Aminosalicylic acid.
Sunitinib may increase the hypoglycemic activities of Aminosalicylic acid.,Sunitinib may increase the blood sugar-lowering effect of Aminosalicylic acid.
The serum concentration of Aminosalicylic acid can be increased when it is combined with Pralatrexate.,The serum concentration of Aminosalicylic acid can be increased when it is combined with Pralatrexate.
The serum concentration of Aminosalicylic acid can be increased when it is combined with Methotrexate.,The serum concentration of Aminosalicylic acid can be increased when it is combined with Methotrexate.
Mesalazine may increase the anticoagulant activities of Aminosalicylic acid.,Mesalazine may increase the blood-thinning effect of Aminosalicylic acid.
Balsalazide may increase the anticoagulant activities of Aminosalicylic acid.,Balsalazide may increase the blood-thinning effect of Aminosalicylic acid.
Olsalazine may increase the anticoagulant activities of Aminosalicylic acid.,Olsalazine may increase the blood-thinning effect of Aminosalicylic acid.
Disopyramide may increase the hypoglycemic activities of Trolamine salicylate.,Disopyramide may increase the blood sugar-lowering effect of Trolamine salicylate.
Tolbutamide may increase the hypoglycemic activities of Trolamine salicylate.,Tolbutamide may increase the blood sugar-lowering effect of Trolamine salicylate.
Miglitol may increase the hypoglycemic activities of Trolamine salicylate.,Miglitol may increase the blood sugar-lowering effect of Trolamine salicylate.
Sulfamethoxazole may increase the hypoglycemic activities of Trolamine salicylate.,Sulfamethoxazole may increase the blood sugar-lowering effect of Trolamine salicylate.
Sitagliptin may increase the hypoglycemic activities of Trolamine salicylate.,Sitagliptin may increase the blood sugar-lowering effect of Trolamine salicylate.
Dapagliflozin may increase the hypoglycemic activities of Trolamine salicylate.,Dapagliflozin may increase the blood sugar-lowering effect of Trolamine salicylate.
Alogliptin may increase the hypoglycemic activities of Trolamine salicylate.,Alogliptin may increase the blood sugar-lowering effect of Trolamine salicylate.
Saxagliptin may increase the hypoglycemic activities of Trolamine salicylate.,Saxagliptin may increase the blood sugar-lowering effect of Trolamine salicylate.
Sulfadiazine may increase the hypoglycemic activities of Trolamine salicylate.,Sulfadiazine may increase the blood sugar-lowering effect of Trolamine salicylate.
Nateglinide may increase the hypoglycemic activities of Trolamine salicylate.,Nateglinide may increase the blood sugar-lowering effect of Trolamine salicylate.
Gliclazide may increase the hypoglycemic activities of Trolamine salicylate.,Gliclazide may increase the blood sugar-lowering effect of Trolamine salicylate.
Pioglitazone may increase the hypoglycemic activities of Trolamine salicylate.,Pioglitazone may increase the blood sugar-lowering effect of Trolamine salicylate.
Mifepristone may increase the hypoglycemic activities of Trolamine salicylate.,Mifepristone may increase the blood sugar-lowering effect of Trolamine salicylate.
Quinine may increase the hypoglycemic activities of Trolamine salicylate.,Quinine may increase the blood sugar-lowering effect of Trolamine salicylate.
Metformin may increase the hypoglycemic activities of Trolamine salicylate.,Metformin may increase the blood sugar-lowering effect of Trolamine salicylate.
Tolazamide may increase the hypoglycemic activities of Trolamine salicylate.,Tolazamide may increase the blood sugar-lowering effect of Trolamine salicylate.
Glimepiride may increase the hypoglycemic activities of Trolamine salicylate.,Glimepiride may increase the blood sugar-lowering effect of Trolamine salicylate.
Empagliflozin may increase the hypoglycemic activities of Trolamine salicylate.,Empagliflozin may increase the blood sugar-lowering effect of Trolamine salicylate.
Repaglinide may increase the hypoglycemic activities of Trolamine salicylate.,Repaglinide may increase the blood sugar-lowering effect of Trolamine salicylate.
Glyburide may increase the hypoglycemic activities of Trolamine salicylate.,Glyburide may increase the blood sugar-lowering effect of Trolamine salicylate.
Bromocriptine may increase the hypoglycemic activities of Trolamine salicylate.,Bromocriptine may increase the blood sugar-lowering effect of Trolamine salicylate.
Quinapril may decrease the antihypertensive activities of Trolamine salicylate.,Quinapril may reduce the blood pressure-lowering effect of Trolamine salicylate.
The risk or severity of adverse effects can be increased when Cilostazol is combined with Trolamine salicylate.,The risk of side effects can be increased when Cilostazol is taken with Trolamine salicylate.
The risk or severity of adverse effects can be increased when Iloprost is combined with Trolamine salicylate.,The risk of side effects can be increased when Iloprost is taken with Trolamine salicylate.
The risk or severity of adverse effects can be increased when Alprostadil is combined with Methyl salicylate.,The risk of side effects can be increased when Alprostadil is taken with Methyl salicylate.
Edoxaban may increase the anticoagulant activities of Sugammadex.,Edoxaban may increase the blood-thinning effect of Sugammadex.
The therapeutic efficacy of Sugammadex can be decreased when used in combination with Toremifene.,The effectiveness of Sugammadex can be reduced when used with Toremifene.
Warfarin may increase the anticoagulant activities of Sugammadex.,Warfarin may increase the blood-thinning effect of Sugammadex.
Phenprocoumon may increase the anticoagulant activities of Sugammadex.,Phenprocoumon may increase the blood-thinning effect of Sugammadex.
Phenindione may increase the anticoagulant activities of Sugammadex.,Phenindione may increase the blood-thinning effect of Sugammadex.
Acenocoumarol may increase the anticoagulant activities of Sugammadex.,Acenocoumarol may increase the blood-thinning effect of Sugammadex.
Dicoumarol may increase the anticoagulant activities of Sugammadex.,Dicoumarol may increase the blood-thinning effect of Sugammadex.
Apixaban may increase the anticoagulant activities of Sugammadex.,Apixaban may increase the blood-thinning effect of Sugammadex.
Rivaroxaban may increase the anticoagulant activities of Sugammadex.,Rivaroxaban may increase the blood-thinning effect of Sugammadex.
Argatroban may increase the anticoagulant activities of Sugammadex.,Argatroban may increase the blood-thinning effect of Sugammadex.
Bivalirudin may increase the anticoagulant activities of Sugammadex.,Bivalirudin may increase the blood-thinning effect of Sugammadex.
Dabigatran etexilate may increase the anticoagulant activities of Sugammadex.,Dabigatran etexilate may increase the blood-thinning effect of Sugammadex.
Edetic acid may increase the anticoagulant activities of Sugammadex.,Edetic acid may increase the blood-thinning effect of Sugammadex.
Fondaparinux may increase the anticoagulant activities of Sugammadex.,Fondaparinux may increase the blood-thinning effect of Sugammadex.
Pentaerythritol tetranitrate may increase the anticoagulant activities of Sugammadex.,Pentaerythritol tetranitrate may increase the blood-thinning effect of Sugammadex.
Citric acid may increase the anticoagulant activities of Sugammadex.,Citric acid may increase the blood-thinning effect of Sugammadex.
Pentosan polysulfate may increase the anticoagulant activities of Sugammadex.,Pentosan polysulfate may increase the blood-thinning effect of Sugammadex.
Protocatechualdehyde may increase the anticoagulant activities of Sugammadex.,Protocatechualdehyde may increase the blood-thinning effect of Sugammadex.
Edoxaban may increase the anticoagulant activities of Trolamine salicylate.,Edoxaban may increase the blood-thinning effect of Trolamine salicylate.
The risk or severity of adverse effects can be increased when Anagrelide is combined with Trolamine salicylate.,The risk of side effects can be increased when Anagrelide is taken with Trolamine salicylate.
Acarbose may increase the hypoglycemic activities of Trolamine salicylate.,Acarbose may increase the blood sugar-lowering effect of Trolamine salicylate.
Sunitinib may increase the hypoglycemic activities of Trolamine salicylate.,Sunitinib may increase the blood sugar-lowering effect of Trolamine salicylate.
The serum concentration of Trolamine salicylate can be increased when it is combined with Pralatrexate.,The serum level of Trolamine salicylate can be increased when combined with Pralatrexate.
The serum concentration of Trolamine salicylate can be increased when it is combined with Methotrexate.,The serum level of Trolamine salicylate can be increased when combined with Methotrexate
Phenindione may increase the anticoagulant activities of Methyl salicylate.,Phenindione may increase the blood-thinning effect of Methyl salicylate.
Acenocoumarol may increase the anticoagulant activities of Methyl salicylate.,Acenocoumarol may increase the blood-thinning effect of Methyl salicylate.
Dicoumarol may increase the anticoagulant activities of Methyl salicylate.,Dicoumarol may increase the blood-thinning effect of Methyl salicylate.
The risk or severity of adverse effects can be increased when Nimesulide is combined with Methyl salicylate.,The risk of side effects can be increased when Nimesulide is taken with Methyl salicylate.
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Methyl salicylate.,The risk of side effects can be increased when Acetylsalicylic acid is taken with Methyl salicylate.
The risk or severity of adverse effects can be increased when Azelastine is combined with Methyl salicylate.,The risk of side effects can be increased when Azelastine is taken with Methyl salicylate.
The risk or severity of adverse effects can be increased when Tranilast is combined with Methyl salicylate.,The risk of side effects can be increased when Tranilast is taken with Methyl salicylate.
Sulfisoxazole may increase the hypoglycemic activities of Methyl salicylate.,Sulfisoxazole may increase the blood sugar-lowering effect of Methyl salicylate.
Chlorpropamide may increase the hypoglycemic activities of Methyl salicylate.,Chlorpropamide may increase the blood sugar-lowering effect of Methyl salicylate.
Canagliflozin may increase the hypoglycemic activities of Methyl salicylate.,Canagliflozin may increase the blood sugar-lowering effect of Methyl salicylate.
Pentamidine may increase the hypoglycemic activities of Methyl salicylate.,Pentamidine may increase the blood sugar-lowering effect of Methyl salicylate.
Glipizide may increase the hypoglycemic activities of Methyl salicylate.,Glipizide may increase the blood sugar-lowering effect of Methyl salicylate.
Disopyramide may increase the hypoglycemic activities of Methyl salicylate.,Disopyramide may increase the blood sugar-lowering effect of Methyl salicylate.
Tolbutamide may increase the hypoglycemic activities of Methyl salicylate.,Tolbutamide may increase the blood sugar-lowering effect of Methyl salicylate.
Miglitol may increase the hypoglycemic activities of Methyl salicylate.,Miglitol may increase the blood sugar-lowering effect of Methyl salicylate.
Sulfamethoxazole may increase the hypoglycemic activities of Methyl salicylate.,Sulfamethoxazole may increase the blood sugar-lowering effect of Methyl salicylate.
Sitagliptin may increase the hypoglycemic activities of Methyl salicylate.,Sitagliptin may increase the blood sugar-lowering effect of Methyl salicylate.
Dapagliflozin may increase the hypoglycemic activities of Methyl salicylate.,Dapagliflozin may increase the blood sugar-lowering effect of Methyl salicylate.
Alogliptin may increase the hypoglycemic activities of Methyl salicylate.,Alogliptin may increase the blood sugar-lowering effect of Methyl salicylate.
Saxagliptin may increase the hypoglycemic activities of Methyl salicylate.,Saxagliptin may increase the blood sugar-lowering effect of Methyl salicylate.
Sulfadiazine may increase the hypoglycemic activities of Methyl salicylate.,Sulfadiazine may increase the blood sugar-lowering effect of Methyl salicylate.
Nateglinide may increase the hypoglycemic activities of Methyl salicylate.,Nateglinide may increase the blood sugar-lowering effect of Methyl salicylate.
Dabigatran etexilate may increase the anticoagulant activities of Pentosan polysulfate.,Dabigatran etexilate may increase the blood-thinning effect of Pentosan polysulfate.
Edetic acid may increase the anticoagulant activities of Pentosan polysulfate.,Edetic acid may increase the blood-thinning effect of Pentosan polysulfate.
